University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

2012

Valproic Acid-Induced Teratogenesis in Japanese Rice Fish
(Oryzias Latipes) Embryogenesis
Mengmeng Wu

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Pharmacology Commons

Recommended Citation
Wu, Mengmeng, "Valproic Acid-Induced Teratogenesis in Japanese Rice Fish (Oryzias Latipes)
Embryogenesis" (2012). Electronic Theses and Dissertations. 319.
https://egrove.olemiss.edu/etd/319

This Thesis is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for
inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information,
please contact egrove@olemiss.edu.

VALPROIC ACID-INDUCED TERATOGENESIS
IN JAPANESE RICE FISH (ORYZIAS LATIPES) EMBRYOGENESIS

A Thesis
presented in partial fulfillment of requirements
for the degree of Master of Science
In the Department of Pharmacology
The University of Mississippi

by
MENGMENG WU
May 2012

Copyright Mengmeng Wu 2012
ALL RIGHTS RESERVED

ABSTRACT
Valproic acid (VPA) was introduced as an antiepileptic in 1967 in France and it has
become the most prescribed anticonvulsive drug therapy worldwide since then. In the clinic,
valproic acid is selected to treat absence seizures, myoclonic seizures, generalized tonic-clonic
seizures, atonic attacks and partial seizures. Epilepsy is the second most common neurologic
disorder that affects pregnant women (0.5%-1%). Approximately 1 out of 250 pregnant women
are taking antiepileptic drugs. Valproic acid is designated as a human teratogen, which induces
major congenital anomalies, facial dysmorphic features, and autistic-like behaviors, which affect
verbal, cognitive, communicative, and social abilities of affected children.
We are developing the Japanese rice fish (Oryzias latipes), also known as Japanese
medaka, as an animal model to study valproate-induced teratogenesis during the period of
embryogenesis. Fertilized embryos of Japanese rice fish at three developmental stages (group A:
0-2 dpf; group B: 1-3 dpf; group C: 4-6 dpf) were exposed to VPA (0-80 mM) for 48 hrs. The
amounts of VPA to cause 50% mortality (LC50), which were observed on 14 day post
fertilization (dpf), are found to be developmental stage-specific. The LC50 for group A (Iwamatsu
developmental stage 4-10) is 1.68 ± 1.55 mM which is much lower than the LC50s for groups B
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(26.45 ±1.64 mM) and C (20.37 ± 3.3 mM) (Iwamatsu developmental stages 17-32). The
development of the cardiovascular system was disrupted by VPA in each treatment group,
displaying increased incidence of thrombus, reduced heart rates, and inhibited or delayed onset
of circulation. The hatching efficiency was also reduced by VPA in each treatment group. The
higher the concentration of VPA the embryos were treated with, the more severe the results were.
The earlier developmental stages the treatments were targeted at, the more deleterious the effects
of VPA were.
VPA also caused malformation of neurocranial and splanchnocranial cartilages of
hatchlings that had been exposed prenatally. The length of neurocranium, quadrate, ceratohyal
and basibranchial 1-3 were all reduced in hatchlings of both groups E (0-2 pdf) and L (4-6 dpf).
Trabeculae, epiphyseal bar, anterior orbital cartilage and basilar plate displayed reduction in
length only in hatchlings of group E. In addition, the significant reduction in the linear length of
polar cartilage and ceratobranchials 1-5 were manifested only in hatchlings of group L. Other
cartilages remained unaltered in both groups E and L. It was indicated that the length of the
neurocranium was reduced due to cumulative reduction of the component cartilages.
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mRNA analyses of nine genes demonstrated that the genes involved with oxidative stress
remained unaltered after valproate exposure. However, the genes involved with neurogenesis
(wnt1, otx2 and nlgn3b) and regulation of cell division (shh and ccna2) showed developmental
stage-specific alteration after valproate exposure.
This study indicates that valproate is able to induce some phenotypic features in Japanese
rice fish which are analogous to human fetal valproate syndrome (FVS), and Japanese rice fish
can be used as a unique alternatively non-mammalian vertebrate model to study
valproate-induced teratogenesis, including FVS.
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CHAPTER 1
INTRODUCTION
1.1 Valproic acid-induced teratogenesis (fetal valproate syndrome and autistic-like
behaviors)
An article in 1992 (Lindhout and Omtzigt, 1992) showed that approximately one out of
every 250 pregnant mothers uses antiepileptic drugs and a large majority of these use valproate as
monotherapy or in the part of polytherapy. Valproic acid (VPA, 2-propyl-pentanoic acid), a short
chain branched fatty acid, was first introduced as an antiepileptic drug in 1967 in France (Perucca,
2002). In 1978, VPA was put on the market in United States to treat convulsive disorders, and has
become widely prescribed worldwide since then. In the clinic, VPA is usually the preferred drug
for treatment of a broad range of seizures, such as absence seizures, myoclonic seizures,
generalized tonic-clonic seizures, atonic attacks and partial seizures. In addition to its
antiepileptic effects, VPA is also used as a mood stabilizer in the treatment of psychiatric illnesses
such as bipolar disorder (depressive-manic phases) (Gyulai et al., 2003; Keck and McElroy,
2003), and migraine (Calabresi et al., 2007). The mechanisms of action of valproate to treat
convulsive disorders are suggested to be multiple. Valproate is known to deter neurons consistent
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repetitive firing frequently in culture. Valproate also has an active effect on Na+ currents. It is also
indicated that valproate can block the NMDA receptor-mediated excitatory currents, and increase
the levels of GABA in the brain probably through improving GABA synthesis and inhibiting its
degradation under the effects of valproate on glutamic acid decarboxylase and GABA
transaminase respectively. Valproate is also approved to inhibit the activity of GAT-1, which is a
GABA transporter, to facilitate GABA levels in the neurons. Through intensive research, valproate
is shown as a potent histone deacetylase inhibitor, however, some scientists (Gurvich et al., 2005)
believed this mechanism of action is where the teratogenic effects of valproate are derived from.
Besides its common functions, VPA is unconventionally used for the treatment of ischemia (Costa
et al., 2006), cancer (Blaheta, et al., 2005), Alzheimer’s disease (Qing et al., 2008), latent HIV
(Lehrman, et al., 2005), terminal blood loss (Alam et al., 2009), and traumatic brain injury (Dash et
al., 2010). The common adverse effects of VPA in the general population are nausea, vomiting,
gastrointestinal complaints (abdominal pain and heartburn) and a fine tremor if patients are taking
a high dose. Other toxic effects of VPA include weight gain, tremor, increased appetite,
hepatotoxicity, thrombocytopenia and alopecia (Terbach and Williams, 2009).
Compared with other antiepileptic drugs (AEDs), such as phenytoin, phenobarbital and
carbamazepine, VPA is designated to be highly toxic if used on pregnant mothers (Dravet et al.,
1992; Kaneko et al., 1999; Kini et al., 2006; Morrow et al., 2006; Diav-Citrin et al., 2008).
2

However, VPA has anticonvulsant effects on many different types of epilepsy and relatively absent
sedative side-effects, compared with carbamazepine and phenobarbitone (Clayton-Smith and
Donnai, 1995). Therefore, VPA is classified as a Pregnancy Category D drug (Dufour-Rainfray et
al., 2011) by the American Food and Drug Administration (FDA), which is defined as although
detrimental effects of VPA on human fetuses are supported by available investigational and
marketing evidence, potential pros of VPA may be weighed over its potential cons, and it becomes
a common therapeutic drug used in pregnancies with epilepsy.
Embryogenesis is subject to the detrimental effects of teratogens (Oxendine et al., 2006).
Compared with mice and rhesus monkeys, human embryos are more susceptible to VPA
(Hendrickx et al., 1988; Ehlers et al., 1992; Ehlers et al., 1996; Al Deeb et al., 2000). Development
of the human embryo can be divided into three crucial periods (Ornoy and Arnon, 1993; Arnon et
al., 2000; Ornoy, 2003; Ornoy, 2006). The first important period is 0-2.5 weeks after fertilization,
which is pre-organogenic. Although embryos in the pre-organogenic period are thought to be not
sensitive to toxicants, highly toxic teratogens may lead pregnancies in this period into abortion or
still birth. The second significant period, which starts from the 3rd week to the 8th week post
fertilization, is active organogenesis, and is theorized to be the most susceptible period (Ornoy,
2009). This theory holds that some toxicants can alter anatomical structures and functions of the
organ to exhibit the damaging effects. The third critical period is the fetal period which continues
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until the fetus is born. The earlier the period of the development the embryos were exposed to the
teratogens, the more severe the deleterious effects were. Therefore, in general, the first trimester of
pregnancy is the most sensitive period, and pregnant mothers need to take precautions to avoid
contacting teratogens. Additionally, the longer the exposure continues, the more damaging the
effects are. Development of the brain continues throughout pregnancy, and hence the brain can
suffer from adverse effects even if exposure to VPA extends beyond the first trimester (Ornoy
and Arnon, 1993; Arnon et al., 2000; Ornoy, 2003; Kultima et al., 2004; Ornoy, 2006). It is
commonly accepted that VPA-induced teratogenic effects are dose and developmental stage
specific (Ornoy and Arnon, 1993; Arnon et al, 2000; Ornoy, 2003; Ornoy, 2006). Therefore, three
developmental stages (0-2 dpf, 1-3 dpf, 4-6 dpf) in Japanese rice fish embryos and several
dosages (2, 5, 10, 20, 40 and 80 mM) were chosen for this project.
The adverse effects of VPA were first reported in 1980 (Dalens et al., 1980). In 1984, Dr.
DiLiberti (Diliberti et al., 1984) proposed a specific term "fetal valproate syndrome" to describe a
well-recognized constellation of major congenital anomalies, dysmorphic features and
neurodevelopmental retardations of children born to mothers taking valproic acid during
pregnancy. Due to ethical constraints, VPA-induced teratogenic effects were investigated by
reported cases in a prospective or retrospective methodology on children born to VPA-treated
mothers during pregnancy. In addition, some subjects were not willing to participate in the
4

investigation, and, therefore, the results could not rule out a self-selection bias. Therefore, there is
no sufficient data to draw the conclusive decisions for the phenotypes of children under the
impacts of VPA-induced teratogenesis. From the available data, the adverse effects of VPA on
embryonic and fetal development are categorized into three aspects (Ornoy, 2009): (1) Elevated
risks of major congenital anomalies including neural tube defects, cardiovascular, orofacial and
digital abnormalities, deformities of eye, skin, abdominal wall, brain, respiratory tract and
genitourinary systems, etc.; (2) A specific syndrome, ‘Fetal Valproate Syndrome’, presented with
facial dysmorphic features (figure 2), but also involves damage to other organs, such as the
neural tube; (3) Neurodevelopmental disorders that affect cognitive, social and verbal skills,
which lead to stereotypic behaviors, such as autistic-like symptoms. The neurodevelopmental
disorders are probably due to neural tube defects and other abnormalities which occur in the
CNS.
Embryonic and fetal VPA exposure correlates with increased risks of neural, craniofacial,
cardiovascular, and skeletal birth defects (Nau et al., 1991 and Nau, 1994), and VPA exposure
induces similar symptoms in a variety of species including amphibians, fish, primates, rodents
and birds (Dawson et al., 1991; Oberemm et al., 1992; Herrmann, 1993; Kratke et al., 1996;
Briner et al., 2000; Pennati et al., 2001). Neural tube defects and cardiac defects, the two most
common congenital birth defects in the human population (Gurvich et al., 2005), also resulted
5

from VPA toxicity with high incidence. Neural tube defects, such as spina bifida, are reported to
occur with 1-2% incidence in all VPA-treated pregnant mothers, and have often been seen in the
lumbar and sacral positions (Dalens et al., 1980; Gomez, 1981; Bjerkedal et al., 1982; Robert et
al., 1983; Lindhout et al., 1992, Omtzigt et al., 1992 and Fried et al., 2004). Lumbosacral
myelomeningocele was observed at 10-20 times the rate in the general population (Dalens et al.,
1980; Gomez, 1981; Bjerkedal et al., 1982; Robert et al., 1983; Lindhout et al., 1992, Omtzigt et
al., 1992 and Fried et al., 2004). Neural tube defects can be generated in the third week post
fertilization. This is generally before the pregnancy can be detected or confirmed. Hence, women
under treatment with VPA at childbearing age should stop usage of VPA before any planned
pregnancy (Ornoy, 2009). Besides neural tube defects and cardiac defects, the major congenital
anomalies also include trigonocephaly, cleft palate and lip, radial ray defects, pulmonary
abnormalities, coloboma of iris/optic disc and digital defects (Kini, 2006). In general, congenital
anomalies in babies born to VPA-treated mothers during pregnancy occur at a 2 to 3 times higher
rate than in the general population (Yerby, 1998; Kozma, 2001). Children with FVS also show
facial dysmorphic features characterized by broad forehead, thin arched eyebrows with medial
deficiency, epicanthal folds with infraorbital grooves, flat nasal bridge, broad nasal root, short
upturned nose, long, smooth and shallow piltrum, downturned mouth, long and thin upper lip, and
thick lower lip (figure 2) (DiLiberti, et al., 1984; Winter, et al., 1987; Clayton-Smith, et al., 1995).
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In addition, valproate treatment of pregnant mothers results in low verbal IQ and autistic-like
disorders (Kini, 2006). As the epidemiological studies indicated, valproate exposure during
pregnancy is associated with increased incidence of autistic-like behaviors of the offspring
(Christianson et al., 1994; Rasalam et al., 2005; Bromley et al. 2008).
Autism spectrum disorder (ASD) is an umbrella term used to define a heterogenous
neurodevelopmental disorder including classic autism, Asperger syndrome, Rett syndrome,
childhood disintegrative disorder and pervasive developmental disorder-not otherwise specified
(PDD-NOS) (Pardo et al, 2007; Lianeza et al., 2010). ASD is described as impairment of cognitive
abilities and deficiencies in social, communicative, and verbal skills (Gaily et al., 2004). ASD is
also accompanied by repetitive and sometime self-injurious actions (Landrigan, 2010). ASD
correlates with attention deficit disorder, and can result in educational problems, especially related
to verbal intelligence (Gaily et al., 2004). However, difficulties in social interactions or
relationships are also found in numerous other neurodevelopmental disorders mentioned in the
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (Bishop et al.,
2007). Thus, use of only behavior criteria to diagnose ASD is not sufficient for diagnosis. Children
with ASD are usually diagnosed before 3 years of age. Macrocephaly is a commonly diagnostic
characteristic relevant to autism (Williams et al., 2008).
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Epidemiological studies indicate increased incidence of ASD worldwide accounting for
about 1 out of every 150 children in the USA with a male to female ratio of 4.3: 1 (West et al, 2009).
It is indicated that ASD is a multigenic disease, and environmental insults with deleterious effects
resulting in gene mutation and epigenetic alterations, particularly when these happen at the critical
developmental stages (Schanen, 2006), represent significant risk factors in development of ASD.
In 2006, resperidone was approved by the FDA to treat irritability in children and adolescents with
ASD, however, resperidone therapy can lead to significant weight gain, metabolic problems,
tardive dyskinesia and neuroleptic malignant syndrome (Hong et al., 1999; Newcomer, 2005). In
traditional Chinese medicine, 'Wu Chi' is a specific term to describe the symptoms that are most
similar to those of ASD (Zhang, 2010). 'Wu Chi' is translated as five retardations, which are
standing-up retardation, toddling retardation, hair-growth retardation, tooth-growth retardation
and echolalia retardation. A prescription involving ginseng is assigned to children with the five
retardations (Zhang, 2010). Ginseng contains many ingredients, such as ginsenosides which are a
group of triterpenoid saponins and steroid glycosides. Ginsenosides can increase neurogenesis in
vivo and in vitro under physiological and pathophysiological circumstances (Lu et al., 2010).
Additionally, ginseng can promote axonal regeneration, and it is also effective in decreasing the
formation of reactive oxygen species to show its potential neuroprotective function (Rudakewich
et al., 2001; Ye et al., 2009; Lu et al., 2010). Children with FVS and/or ASD need elaborative care
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and particular service due to their poor verbal and coordinative skills and musculoskeletal
deficiency. Children may need extra help at school and even one to one help due to the existent
learning problems (Kini, 2006). Toilet training may also be highly affected, and affected children
need significant training to acquire it. Physiotherapy is provided for children with motor
developmental delay. Surgical intervention before the age of 6 months (Lajeunie, et al., 2001) to
correct craniosynostosis can also be beneficial for the affected children.
Since valproic acid is a teratogen, its use during pregnancy is necessary to be considered
cautiously. The daily dose of VPA during pregnancy is recommended to be below 1000mg and
divided into 2-3 individual doses. The serum level of VPA needs to undergo minimal fluctuations
when taking these 2-3 doses per day (Yerby, 2003; Alsdorf and Wyszynski, 2005; Diav-Citrin et
al., 2008). Dosages above 1000mg of VPA are associated with elevated risks of teratogenic
effects (Ornoy, 2009). Vitamins of vitamin E and vitamin B family (vitamin B6, B9 and B12),
especially folic acid, are indicated to have potential protective effects for embryos and fetuses
(Elmazar et al., 1992; Al Deeb et al., 2000; Yerby, 2003). It is accepted that folic acid is aiding
rapid cell division to prevent neural tube defects, and hence it is recommended that women take
4-5 mg per day before planned conception and during the first 2-3 months of pregnancy. For
women who could not find alternative medications for VPA, it is advised that the potential
protective reagents, such as vitamin B6, B9, B12 and methionine, are prescribed at
9

preconception and during pregnancy. In addition, follow-up examinations are needed to detect
the status of the fetus before it is born (Ornoy, 2009).
1.2 Animal Models:
A spectrum of structural and neurobehavioral anomalies arise in the development of human
embryos fetuses due to the toxicity of VPA, most appropriately termed as fetal valproate syndrome.
Intensive researches have been done to determine the potential mechanisms underlying
VPA-induced teratogenesis, but none of them have provided conclusive results. Human studies of
FVS are restrained due to ethical constraints. However, several non-human animal models from
mammals to non-mammals have been utilized to explore the molecular mechanisms of this
disorder. Multiple mechanisms can lead to damage to embryos exposed to VPA, and certain animal
models are specialized to study some specific aspects of these processes. Therefore, the choice of
animal model is of vital importance in the investigation of FVS. Each animal model system has its
own pros and cons, according to the addressed questions (Cudd, 2005) and comparisons between
species are informative in investigating gene function and genome evolution (Wang et al., 2006).
Among the animal models used for mechanistic studies of ASD, rats and mice are the preferred
models because they are mammals, phylogenetically more close to human, and detailed behavioral
phenotypic data are available in many of the rodent strains (Halladay et al., 2009). However,
non-mammalian vertebrates and invertebrates are valuable as high-throughput experimental
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models to investigate how the nervous system performs normally and the effects of various
environmental stimulants on the nervous system (Halladay et al., 2009). Although the hearts of
fish and human beings possess essentially different anatomy, their heart morphogenesis,
vasculogenesis and hematopoiesis are accurately controlled by conserved genetic programs in
vertebrates (Lambrechts and Carmeliet, 2004). Another advantage of fish models over the
mammalian models is that the embryos can survive and continue to grow even if the blood
circulation is completely absent due to small sizes and low metabolism. This allows observation
for many days, while mammals under the same condition will die early (Lambrechts and Carmeliet,
2004).
Japanese rice fish (Oryzias latipes), the Far East cousin of zebrafish, and zebrafish (Danio
rerio) derived from a common ancestor about 140 million years ago (wittbrodt et al., 2002). Both
of them are rapidly emerging as important fish models for research on developmental biology and
toxicology (Wang et al., 2006), and interaction between biological living items and their
environment. One benefit of applying the fish models rather than mammalian models includes
their external (outside the body of the mother) fertilization and embryonic development (fertilized
eggs and larvae), which avoids maternal/placental/fetal influences on embryo development.
Another benefit is the transparent chorions covering the embryos. Therefore, investigators can
observe the developmental conditions of embryos, such as their onset of circulatory system and
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normal/abnormal heart formation, directly (Wu et al., 2008). Additionally, fish models possess the
characteristics of easy availability, low maintenance cost, short life cycle and their accessibility to
studies of the gene function (Wittbrodt et al., 2002; Furutani-Seiki and Wittbrodt, 2004). Therefore,
fish models are currently emerging as alternatives to mammalian models. Large-scale mutagenic
screens in zebrafish and Japanese rice fish have revealed several orthologue genes that are highly
correlated to those involved in human genetic diseases (Naruse et al., 2004).
In zebrafish, VPA-induced teratogenic effects have been investigated by many
investigators and the data were almost identical with other models. More specifically, retardation
and cessation of embryonic development, yolk and cardiac edema, brain deformities,
malformations of eye, otoliths and somites, cardiovascular defects, skeletal deformities including
shortened and bent tail (Herrmann, 1993; Selderslaghs et al., 2009) were observed in zebrafish
embryos and hatchlings after developmental VPA exposure. However, VPA analogs such as
valpromide were found to be weak in producing teratogenic activity in zebrafish compared to VPA
alone (Herrmann, 1993; Gurvich et al., 2005). S-valproate is associated with a significant increase
in intersomitic vessel defects in zebrafish embryos (Isenberg et al., 2007). Moreover, VPA
interfered with liver and exocrine pancreas formation in zebrafish during embryogenesis (Farooq
et al., 2008). Furthermore, VPA suppresses seizure-like behavior and improves learning ability in
adult zebrafish treated with pentylenetetrazol (Lee et al., 2010). The teratogenic effects of VPA in
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zebrafish are thought to be mediated through the inhibition of HDACs (histone deacetylases)
(Gurvich et al., 2005; Menegola et al., 2006; Cao et al., 2009). Several laboratories have
established zebrafish as an applicable animal model to study mechanisms of VPA toxicity and/or
autism spectrum disorders (ASDs), and developing another fish model for comparative studies can
increase persuasive abilities of the results and allow opportunities for improvement (Wang et al.,
2006). Besides genome size strength of Japanese rice fish if compared with genome size of
zebrafish (800 Mb in Japanese rice fish and 1700 Mb in zebrafish), only the Japanese rice fish and
its nearest relative, Oryzias curvinotus, are the known non-mammalian vertebrates where the sex
determining gene DMY has been identified and characterized (Matsuda, 2005; Matsuda et al.,
2002, 2003). Therefore, Japanese rice fish may be an excellent alternative non-mammalian animal
model if we are looking forward to verifying what, if any, effects the gender might have in VPA
toxicity. Japanese rice fish exhibit another advantage over zebrafish due to the fact that their
cardiovascular development conforms mostly to the common embryonic circulatory pattern
investigated in other vertebrates including the human, whereas the zebrafish has a distinctly
different pattern (Fujita et al., 2006).
In Japanese rice fish, the embryonic development of the cardiovascular system has been
thoroughly studied by several investigators (Iwamatsu, 2004; Fujita, 2006). Since Japanese rice
fish grow distinct yolk veins, these may be exploited as target sites to study the effects of VPA on
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the cardiovascular system (Wang et al., 2006). Therefore, the structure and development of the
cardiovascular system needs to be understood if we intend to know the significance of
time-dependent treatments. Table 3 outlines every developmental phase of the cardiovascular
system in the embryos of Japanese rice fish. Japanese rice fish embryos after Iwamatsu stage 25
can be compared to fetuses, since these embryos (Iwamatsu stage 25 and onwards) have a
well-developed cardiovascular system, several organs including the brain (organogenesis) and
pectoral fin buds share corresponding features with human fetuses (Hu et al., 2006).
1.3 Metabolism of valproic acid
80-90% of consumed VPA binds to plasma proteins and is conjugated in the liver of
human beings (Kini, 2006). VPA exhibits its toxicity to the fetus and becomes concentrated in
the fetal compartment by diffusion across the placenta instead of placental binding (Nau H.1982;
Albani et al., 1984; Bailey and Briggs, 2005). The highest ratio of VPA serum concentration in
fetuses to that in mothers can be 6, and mean ratios are 1.4-2.4 (Ornoy, 2009). This means that
the fetus is exposed to a much higher concentration of VPA than the mother (Clayton-smith and
Donnai, 1995; Ornoy, 2009). In 1984, Albani (Albani et al., 1984) reported that low
concentrations of VPA are excreted into human milk (less than 5% of the weight-adjusted daily
dose that taken by mothers) (Von et al., 1984; The WHO Working Group, 1988). Therefore,

14

lactation and breast feeding by VPA-treated mothers is allowed (Albani et al., 1984; Von et al.,
1984; The WHO Working Group, 1988).
1.4 Potential Molecular Mechanisms of toxicity of VPA and autism:
The mechanism(s) by which VPA induces anticonvulsant, antimanic, and teratogenic
effects are unknown, but some reports suggest that the medical and the teratogenic effects of VPA
are different. Several studies indicate that teratogenic effects of VPA may be related to folic acid
deficiency, induction of oxidative stress, and inhibition of HDAC (Ornoy, 2009). Furthermore,
VPA influences gamma aminobutaric acid (GABA) synthesis and breakdown (Loscher, 2002;
Calabresi et al., 2007), reduces de novo inositol synthesis (Agam et al., 2002; Shaltiel et al., 2007)
and ion channel activity, causes inositol triphosphate depletion (Berridge et al., 1989; Eickholt et
al., 2005; Shimshoni et al., 2007), regulates fatty acid signaling and turnover (Bazinet et al., 2006),
and activates the mitogen activated protein (MAP) kinase pathway (Hao et al., 2004). VPA is also
associated with carnitine depletion (Coulter, 1991), which affects mitochondrial fatty acid
metabolism leading to hepatotoxicity, and hepatocellular necrosis can happen. Syndromic ASD
accompanied by tuberous sclerosis, neurofibromatosis or macrocephaly presents abnormal
cellular/synaptic growth rate, and this is because mTOR/PI3K pathway was activated by mutated
TSC1/TSC2, NF1, or PTEN (Pardo and Eberhart, 2007; Bourgeron, 2009). Neurexin, which is a
presynaptic protein, interaction with the postsynaptic adhesion molecule neuroligin, is necessary
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for synaptic maturation and synaptogenesis (Bourgeron, 2009). Neuroligin then interacts with the
scaffold protein Shank, which activates other scaffold proteins, such as PSD-95. This regulates
AMDA, NMDA and GABA receptors in the postsynaptic membranes and affects the balance
between excitatory and inhibitory electrical currents (Sudhof, 2008; Bourgeron, 2009). This
nrxn-nlgn-shank pathway is, therefore, suggested to be related to the causes or symptoms of ASD.
In addition, signaling molecules, such as neurotrophin (for example, brain-derived neurotrophic
factor (BDNF)), Reelin, hepatocyte growth factor, and neurotransmitters such as serotonin and
glutamate, are also thought to be involved in the pathogenesis of ASD (Pardo and Eberhart,
2007). VPA-induced teratogenesis probably derives from the interactions between VPA and
several genes and proteins in humans at some certain critical developmental stages. These
interactions alter the expression of several genes and result in modification of protein function.
In our study, we examined several genes to investigate their expression pattern under the
treatment of VPA. Catalase, gst and gr are oxidative stress-related genes, and were used to
investigate whether VPA has a toxic effect through an oxidative stress-related pathway. The
another five genes, nlgn3b, iro3, wnt1, otx2, shh, are expressed in the brain of Japanese rice fish
embryos and are involved in neurogenesis. The other two genes, cyclin a2 and shh, are
associated with cell division. Most of these genes were reported to be expressed in Japanese rice
fish embryos during morphogenesis (Kage et al., 2004: Wu et al., 2008, 2011), and are altered by
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valproate in human and rat (Graf et al., 1998; Bambini-Junior et al., 2011; Tung and Winn, 2011).
Iro3, otx2, shh, wnt1 are transcription factors expressed in the neural tube of Japanese rice fish
embryos at early developmental phases and are implicated importantly in brain morphogenesis
(Kage et al., 2004). The gene, iro3, belongs to the Iroquois family of homeoproteins and is
constitutively expressed in vertebrates, flies, and nematodes (Gomez-Skarmeta and Modolell,
2002). In zebrafish, iro3 has been shown to be required for correct organizer function (Kudoh
and Dawid, 2001). The gene, otx2, is recognized as an early head-domain marker (Blitz and Cho,
1995; Pannese et al., 1995). The wnt1 gene family involves several signaling molecules showing
many biological effects in the formation of the mesoderm of the gastrula (Christian and Moon,
1993; Hoppler et al., 1996; Hoppler and Moon, 1998) and the neural ectoderm (McGrew et al.,
1995, 1997) at the dorso-ventral axis during cleavage stages (Moon and Kimelman, 1998). The
gene, shh, plays a critical role in cell proliferation, differentiation and patterning by activating the
hedgehog signaling pathway. The shh gene is expressed in several organs, including the lung
(Bellusci et al., 1997), the fin ray (Laforest et al., 1998), the epidermis (Sire and Akimenko,
2004), somites (Fan and Tessier-Lavigne, 1994; Johnson et at., 1994; Fan et al., 1995), limb and
fin buds (Krauss et al., 1993; Laufer et al.,1994), and teeth (Bitgood and McMahon, 1995; Iseki
et al., 1996; Koyama et al., 1996). The cyclins, and their cyclin-dependent kinase partners the
Cdks, are the basic components of the machinery that regulates the passage of cells through cell
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cycle. These selected genes were used to investigate the potential bio-signaling pathways
involved in VPA-induced pathogenesis.
1.5 Hypothesis and objectives of the study:
It was revealed by human epidemiological studies that embryos in utero exposed to VPA
during the first trimester (first 12 weeks) of pregnancy are associated with high risk of
VPA-induced teratogenesis including fetal valproate syndrome (FVS) and autism spectrum
disorders (ASDs) in the offspring (Christianson et al., 1994). This indicates that VPA-induced
deleterious effects are developmental stage-dependent. Three developmental stage groups (0-2 dpf,
1-3 dpf, 4-6 dpf) of Japanese rice fish embryos were chosen to investigate the effects of VPA.
Differentiation and migration of neural crest cells (NCCs) during embryogenesis determines
craniofacial cartilages and bones formation. Therefore, any alteration in embryonic differentiation
and migration of NCCs may affect the structure of craniofacial cartilages and bones (Wang et al.,
2006). In Japanese rice fish, the excision of the neural crest on embryos at the neurula stage will
lead to defects in craniofacial cartilages and bones (Langille and Hall, 1988). During
embryogenesis, the heart initiates function as the first organ prior to the advancement of other
organs, and normal development and function of the cardiovascular system is very crucial for the
growth of embryos of Japanese rice fish. Since embryos are supplied with nutrients that come from
yolk by circulation, any disruptions occurring to circulation/circulatory system by VPA will
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prohibit embryos from normal development (Hu et al., 2006). Development of the cardiovascular
system and the craniofacial cartilages of fish models are subject to exogenous chemicals, such as
alcohol (Wang et al., 2006). Children affected with FVS have congenital major malformations
occurring in the cardiovascular system and the neurological system with characteristic facial
dysmorphisms. Therefore, cardiovascular and craniofacial features were investigated and used as
the phenotypic parameters to study VPA-induced teratogenesis in Japanese rice fish.
The present study had three main objectives. First, to determine the validity of VPA as a
teratogen in Japanese rice fish by comparison with those effects previously observed in
VPA-treated zebrafish and mammalian models. Second, the molecular mechanisms that are
suggestive to be related to VPA-induced teratogenesis (ASD and/or FVS) in humans will be
investigated by studying gene expression patterns in Japanese rice fish. Finally, the applicability of
the Japanese rice fish as an alternative animal model for future research on FVS and/or ASD will
be studied. In this regard we have analyzed several morphological parameters including
neurocraniol and splanchnocranial cartilages and mRNA expression patterns of several genes
which are expressed during Japanese rice fish embryogenesis (Wu et al., 2008, 2011). Our data
indicate that VPA is able to induce teratogenic effects in Japanese rice fish. These include yolk
edema, malformed neurocranium and splanchnocranium, decreased hatching efficiency, reduced
heart rate, increased thrombi formation, inhibited onset of blood circulation, and altered
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expression of several genes, the orthologs of which have been shown to have the potential to
induce ASD in humans. Japanese rice fish (Oryzias latipes) embryo-larval development has been
used as a unique non-mammalian model to study the molecular mechanism of FVS.
Epidemiological studies in humans indicate that VPA exposure during pregnancy induces higher
incidence of autism in the offspring (Christianson et al., 1994; Rasalam et al., 2005; Bromley et al.,
2008). Therefore, teratogenic studies with VPA may throw light on understanding the mechanisms
associated with ASD.
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Figure 1: Chemical structure of valproic acid (Chateauvieux, et al., 2010)
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Table 1: Specific features related to fetal valproate syndrome (Kini, 2006)
Neural tube defects
Trigonocephaly
Radial ray defects
Pulmonary abnormalities
Coloboma of iris/optic disc
Low verbal IQ
Autism and autism spectrum disorder
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Figure 2: Child with facial dysmorphic features of FVS: trigonocephaly, which has been
surgically repaired, broad forehead, thin arched eyebrows with medial deficiency, flat nasal
bridge, infraorbital grooves, broad nasal root, short anteverted nose, long, shallow, and smooth
philtrum, long and thin upper lip, and thick lower lip (Kini, 2006).

broad forehead
thin arched eyebrows with
medial deficiency

flat nasal bridge
infraorbital grooves

broad nasal root

short anteverted nose
long, shallow and smooth philtrum
long and thin upper lip
thick lower lip
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Table 2: Anomalies associated with valproate exposure (Kini, 2006)
Neural Tube Defects

Congenital Heart Defects

Limb Defects

Spina bifida

Ventricular septal defect

Radial ray defect

Anencephaly

Atrial septal defect

Polydactyly

Aortic stenosis

Split hand

Patent ductus arteriosus

Overlapping toes

Anomalous right pulmonary artery

Camptodactyly
Ulnar or tibial hypoplasia
Absent fingers
Oligodactyly

Genitourinary Defects

Brain Anomalies

Eye Anomalies

Hypospadias

Hydranencephaly

Bilateral congenital cataract

Renal hypoplasia

Porencephaly

Optic nerve hypoplasia

Hydronephrosis

Arachnoid cysts

Tear duct anomalies

Duplication of the calyceal system

Cerebral atrophy

Microphthalmia

Partial agenesis of corpus callosum

Bilateral iris defects

Agenesis of septum pellucidum

Corneal opacities

Lissencephaly of medial sides of occipital lobes
Dandy-Walker anomaly
Abdominal Wall Defects

Respiratory tract anomalies

Skin abnormalities

Omphalocoele

Tracheomalacia

Capillary haemangioma

Lung hypoplasia

Aplasia cutis congenita of scalp

Severe laryngeal hypoplasia
Abnormal lobulation of the right lung
Right oligaemic lung
*Rare structural abnormalities are shown in italics.
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Table 3: Phenotypic features of the cardiovascular system development of Japanese rice
fish (Iwamatsu, 2004)
Iwamatsu
stage

Hpf

Description

22

~38

The heart becomes visible.

23

~41

The blood vessels (Cuvierian ducts and vitello-caudal vein or marginal
vein) and the intermediate cell mass (ICM) or blood island become
obvious.

24

~44

The hearts begins beating with very low heart rate (32-64 beats/min), and
the embryonic erythrocytes and hemangioblasts are gathered in ICM
during this period.

25

~50

The heart rate rises (70-80 beats/min) and the globular blood cells come
out from the ICM (onset of circulation).

28

~64

The blood cells display flattenly.

29

~74

The embryonic heart starts to differentiate into atrium, ventricle, sinus
venosus and bulbous aorta.

30

~82

Arteries starts to branch to provide trunk muscles, gills and brain with
blood.

34

~121

The circulation to the pectoral fin takes place.

36

~144

The looping of heart is accomplished.

25

CHAPTER 2
MATERIALS AND METHODS
The institutional animal care and use committee (IACUC) of the University of
Mississippi has approved all of the experimental animal protocols. Methods of animal
maintenance, embryo collection, alcian blue staining of hatchlings, RNA extraction, purification
and semi-quantitative relative (RT-PCR) techniques have been previously described
(Dasmahapatra et al., 2005; Wang et al., 2006, 2007; Hu et al., 2008, 2009; Wu et al., 2008,
2011). The research procedure used Japanese rice fish embryos and hatchlings. Each group
consisted of 8-16 embryos and each experiment was repeated 3-5 times.
2.1. Fish maintenance: Adult males and females (orange-red variety, d-rR strain) Japanese
Rice fish

(Oryzias latipes) were maintained in a AHAB Stand-Alone recirculating system

(Aquatic Habitats), which is a Japanese Rice fish housing system, at 25 ± 1 °C, 16L:8D
photoperiod in balanced salt solution (BSS, 17 mM NaCl, 0.4mM KCl, 0.3 mM MgSO4, 0.3
mM CaCl2 in nano-pure water), keeping salinity at 1-1.2 ppt and pH 7.4. The Japanese rice fish
were fed with a combination of tetramin flakes (Tetra) and live brine shrimp twice a day. The
brine shrimp eggs were purchased from Ocean Star International, Inc. (10880 Wiles Road,
26

Coral Springs, FL 33076). Brine shrimp eggs hatched after being maintained in salty water (30
g/L NaCl) and aerated for 48 hrs at 25 ± 1 °C.
2.2. Treatments used to investigate the lethal concentrations of valproic acid and the
effects of valproic acid on hatching efficiency and on the cardiovascular system at three
different time points: The clustered fertilized embryos were collected and separated manually
by gently rubbing over a 20.3 cm (diameter) × 2.5 cm (depth) brass sieve (Fisher Scientific
Company) with openings that are 300 µm. The status of each embryo was checked under a
phase contrast microscope (AO Scientific Instruments, Model: 1820) and the viable embryos
were kept for future research. The developmental stages of embryos were identified and
categorized as Iwamatsu described previously (2004). Three developmental stages of Japanese
rice fish embryos were tested (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6 dpf). Fertilized
embryos with intact chorion within ~4h, 24 h (~1 day) or 96 h (~4 day) post fertilization (dpf)
were exposed to VPA (0-80mM) for 48 hours with a one time change of

medium at the same

concentration of VPA at 24 h. After 48 hrs exposure, the embryos were transferred to clean
hatching solution in 48 well culture plates (one embryo/well/ml hatching solution) without VPA
and with a 50% static renewal of the medium per day until 14 dpf. The hatching solution
contained 0.0002% methylene blue (MB) to prevent fungal growth.
2.3 Lethal concentrations of valproic acid determined on embryos of Japanese rice fish
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exposed at three different developmental stages: The unhatched embryos were maintained in
the 48 well culture plates until 14 dpf. The embryos without heartbeats on 14 dpf would be
considered dead. The LC50 values (mortality of embryos) for VPA in three different
developmental stage groups were obtained by 14 dpf.
2.4 VPA effects on hatching efficiency of Japanese rich fish: Under the experimental
conditions of 25±1°C, 16L: 8D light cycle mentioned above, embryos began hatching after 7
dpf. The development of the embryos treated with VPA was comparatively delayed, and
therefore the alive but unhatched embryos were maintained in 48 wells culture plates until 14
dpf. The embryos that hatched earlier were recorded. The final hatching efficiency (cumulative
hatching incidence of embryos at each developmental stage) was determined on 14 dpf.
2.5 Analysis of deleterious effects of VPA on the cardiovascular system of Japanese rice
fish: The cardiovascular system (circulation status and development of thrombi) of the embryos
was examined on 6 dpf under the phase contrast microscope (AO Scientific Instruments) with a
50% static renewal of VPA free medium each day. The heart rates and circulation status can be
investigated according to the developmental stage maps that were established by Iwamatsu
(2004). The embryos were in circulating state when there was blood flowing through any of the
circulation vessels. When blood was not flowing even through a single vessel the embryos were
considered as in non-circulating state. The heart rate in beats per minute of each embryo was
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determined on 6, 7 and 8 dpf in ovo.
2.6. Morphometric analysis of craniofacial cartilages in Japanese rice fish hatchlings
exposed to VPA.
2.6.1. Treatments: The alive embryos were obtained and separated according to the method
described above (Paragraph 2.2). Embryos at two different developmental time points (Early
developmental stage: 0-2 dpf; Late developmental stage: 4-6 dpf ) were transferred to 48 wells
culture plates and exposed to 1 ml hatching solution or 1ml

hatching solution with 2 mM VPA

(1 embryo/ml/well). Exposure was for 48 hrs with changing of the corresponding medium at 24
hrs. After 48 hrs exposure, the embryos were washed twice with clean hatching solution and
maintained in 1 ml hatching solution until hatching with a 50% static daily renewal of clean
hatching solution. Ordinarily, the embryos begin to hatch after 7 dpf. Since VPA can lead to
developmental delay, embryos were maintained in hatching medium until 14 dpf.

To avoid

post hatching growth, within 24 hrs after hatching the hatchlings were preserved in 4%
paraformaldehyde.
2.6.2. Cartilage staining: The neurocranial cartilages of hatchlings were stained with 0.1 %
Alcian blue (Sigma-Aldrich, St. Louis, MO) following the protocol used in Zebrafish by Carvan
et al. (2004) with minor modifications. After hatching, the hatchlings (8 or 16 per group) were
anesthesized in MS222 (Tricaine methanesulfonate) (0.1% in hatching solution: Sigma-Aldrich,
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St. Louis, MO), and then fixed in 4% paraformadehyde (Sigma-Aldrich, St. Louis, MO) in
phosphate-buffered saline (PBS) with 0.1% Tween 20 (PBT) at 4 0C for 24 hrs. The fixed
hatchlings were washed with nanopure water twice and then treated with 5% TCA for 10 mins.
The TCA-treated hatchlings were washed briefly with acid ethanol (0.37% HCl, 70% ethanol),
and stained in 0.1% Alcian blue for 6 hrs. Excess stain was washed away with ethanol. 1%
trypsin was used to digest the muscle tissues of the stained hatchlings at 37 0C for 3-4 hrs until
all the muscles disappeared as determined by the absence of dark spots in the view as it
appeared under the phase contrast microscope. The samples were finally preserved for
long-term use in 70% glycerol at 4 0C after washing with glycerol-KOH (50% glycerol and
0.25% KOH).
2.6.3. Morphometric analysis: The neurocranial and splanchnocranial cartilages, stained with
Acian blue, were investigated under an Olympus BX 40F-3 microscope to analyze the effects of
VPA exposure during embryonic development. The entire neurocranium and splachnocranium
were captured as photomicrographs using the microscope at fixed magnification (100X/40X).
Most of the photomicrographs were captured at 100X magnification, and some were at 40X
magnification. The linear lengths of the cartilages of the neurocranium and the
splanchnocranium were measured using imaging software (Media Cybernetics, Silver Springs,
MD). The length of the cartilages were calculated by pixel values and multiplying by the
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corresponding magnification factor. After staining with Alcian blue, the ethmoid plate (EP) with
lamina orbitonasalis, paired trabeculae (TB), anterior orbital cartilage (AOC), posterior orbital
cartilage (POC), epiphyseal bar (EB), basilar plate (BP) with anterior (ABC) and posterior
(PBC) basicranial commissures, hypophyseal plate (HP) with paired polar cartilages (PC), and
auditory capsules in the neurocranium could be visualized. In the splanchnocranium, Meckel’s
cartilage (MC), pterygoid processes (PT), quadrate (QU), hyosymplectic (HYS), hyoid (HYO),
basihyal (BH), ceratohyal (CH), 4 basibranchials (BB), 3 pair hypobranchials (HBR), 5 pair
ceratobranchial (CBR), 4th epibranchial (EBR) and 4th hypobranchial (HBR) are also clearly
identifiable (Figures 6-7). The nomenclature of the cartilages used in this communication was
defined by Langille and Hall (1987). In the present experimental conditions, generally embryos
of group E exposed to 5 mM VPA and above, were unable to hatch even after 14 dpf. In group
L, less than 25% of embryos exposed to 5 mM VPA were able to hatch. Therefore, only data for
hatchlings of groups E and L exposed to 2mM VPA prenatally are presented. The individual
cartilages and the entire neurocranium were used for morphometrical analysis. In the
neurocranium, EP, AOC, EB and BP are linear, and therefore were measured directly. TC and
PC are not always of equal size in the left and right sides, and hence both sides were measured
individually and an average was calculated. The linear length of ABC was measured from the
anterior end of the ABC to the head of the notochord on both sides and then averaged. In the
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splanchnocranium, QH, BH, CH, BB (1-4), CBR (1-4) are linear and were measured directly.
BB 1-3 can not be identified visually, and thus the total length of BB 1-3 was considered as one
parameter. BB 4 is separated from BB 1-3 visibly, and thus was measured individually. The
lower jaw (MC) is curved, and therefore the length was determined from the joint points of two
parts of the lower jaw (MC) to the midpoint of an imaginary line drawn linking the lower jaws
ends. The 5th CBR is also curved and its length was decided as the distance between the
meeting points of the left and right 5th CBRs and the central of an imaginary line drawn to link
the anterior end of the pharyngeal teeth. The POC, auditory capsule, PBC in the neurocranium,
and PT, HYS, HYO in the splanchnocranium are irregularly shaped and consequently were not
used for morphometric analysis (figures 6-7).
2.7. Biochemical analysis of Japanese rice fish embryos exposed to valproic acid
RNA was extracted from the intact embryo (embryos with yolk) by Trizol reagent
(Wang et al., 2007). The primers used for rRT-PCR of mRNAs of several genes (catalase, gr,
gst, iro3, nlgn3b, otx2, wnt1, shh and ccna2) are mentioned in Table 8.
2.7.1. Treatments: Japanese rice fish embryos were exposed to varying concentrations of VPA
at three different time points of development (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6
dpf). Exposure was discontinued after 48 hours following a one time renewal of the medium at
24 h. In addition to controls, embryos in A group were exposed to 1 mM and 2 mM VPA, and in
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B and C groups were exposed to 2 mM, 5 mM. For RNA extraction, the embryos were washed
with hatching solution twice and homogenized immediately after completion of the 48 hr
exposure to VPA.
2.7.2. Isolation of RNA: The total RNA was extracted from Japanese rice fish embryos by
using Trizol reagent (Invitrogen, Carlsbad, CA), following the manufacturer's instruction. 0.5
ml of Trizol was added to each tube, which contained 6-8 embryos from the same treatment
group. These were then homogenized and centrifuged (Labnet International, Inc., Edison, NJ;
model: PRISM R) at 12,000 X g for 20 mins at 4 0C. The upper clear phase was removed to a
1.5 ml clean centrifuge tube, to which was added 0.25 µl of isopropanol (Sigma-Aldrich, St.
Louis, MO, USA). The mixture was incubated at room temperature for 10 minutes, and
centrifuged again at 12, 000 X g for 20 mins at 4 0C. The precipitate was cleaned with a 1 ml
75% ethanol wash. DNA from the washed RNA was removed by treating the samples with
DNase I (Promega, Madison, WI). The final 50 ul volume containing one unit of DNase I, 1 X
transcription buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 0.5 mM MnCl2) and 40 U of
RNAsin (Promega, Madison, WI) was added to the 75% ethanol-washed RNA.

After

incubation at 37 0C for 20 mins, the DNase I was removed by the same methods of Trizol
precipitation. The purified RNA was stored at -80 0C. The concentration of RNA was obtained
with an Eppendorf Biophotometer. The purity of the RNA was determined by distinct 18S and
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28S ribosomal RNA using 1% agarose gel electrophoresis with 0.1% ethidium bromide, and the
ratio of absorbance at wavelength 260 nm and at 280 nm is over 1.5.
2.7.3. Semi-quantatative RT-PCR: A first strand cDNA synthesis protocol (Invitrogen,
Carlsbad, CA) was followed to synthesize cDNA by using 1 µg of DNA-free total RNA. The
cDNA was synthesized in a 20 ml reaction volume that included 4 µl 5 X buffer (composition),
1 µl 10 mM dNTPs, 1 µl 10 mM DTT, 1 µl oligo dT and 200 U of superscript Ш RNA
polymerase (Invitrogen, Carlabad, CA) at 50 0C for 1 h. 1 µl of synthesized cDNA in a final
volume of 20 µl was used to detect the expression levels of several transcription factor mRNAs
by semi-quatitative PCR. The 20 µl reaction mixture contained 10 µl of 2 X buffer (composition)
(Qiagen, Valencia, CA), 1 µl cDNA, 50 pM each of forward and reverse primers of the target
genes and 50 pM each of forward and reverse primers of the internal control (beta-actin).

The

amplification reaction for semi-quatitative PCR was carried out in a PTC-200 Peltier Thermal
cycler (Opticon 2 MJ Research, Reno, NV).

30 cycles of denaturation at 94 0C for 30 s,

annealing at 60 0C for 1 min and extension at 72 0C for 2 mins followed initial denaturation at
94 for 2 mins. The final step was extension at 72 0C for 7 mins. 5 µl of the reaction product was
separated using 2% agarose gel electrophoresis (100 voltages; room temperature) containing
0.1% ethidium bromide (µg/ml) and two bands, one of the target gene and one of the internal
control,

appeared under 290-365 nm ultraviolet light. The gel electrophoresis pictures were
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taken using a Versadoc Imaging System (BioRad, Hercules, CA; Model: 3000) and the band
intensities of the target gene and the internal control were determined using image analysis
software (Quantity One, BioRad). The results were expressed as the ratio of relative band
intensity of target gene to the band intensity of the β-actin gene.
2.8. Statistical analysis: LC50s were calculated from transformed data ( log valproate
concentration) using a nonlinear regression (curve-fit) program (Graph-Pad Prism, version 5,
San Diego, CA). All other data (thrombi, vessel circulation, heart rate and hatching efficiency)
were analyzed by using one way ANOVA followed by Tukey's multiple comparison post-hoc
test. The rRT-PCR data were transformed (log ratio of band intensity of target gene to the band
intensity of the β-actin gene) before analysis. For skeletal cartilages endpoint measurement, the
data were analyzed by unpaired Student's t test. The results were expressed as mean ± SEM of
3-4 independent experiments and P<0.05 was considered significant.

35

CHAPTER 3
RESULTS
3.1 Lethal concentration of valproic acid on Japanese rice fish developmentally and
prenatally exposed at different developmental stages.
Three developmental stages of Japanese rice fish embryos were set as three different
treatment groups and tested (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6 dpf). Fertilized
embryos of Japanese rice fish with intact chorion were exposed to valproate (0-80 mM) for 48
hrs during these three developmental stages with a one time change of the medium at 24 hr and
then transferred to clean hatching solution without valproate. On day 14 post fertilization (dpf),
the calculated LC50 values for valproate as determined from three separate independent
experiments (group A has six separately independent experiments, groups B and C has three
separately independent experiments) were 1.68 ± 1.55 mM with 0-2 dpf (group A) , 26.45 ± 1.64
mM with 1-3 dpf exposure (group B) and 20.37 ± 3.3 mM with 4-6 dpf exposure (group C)
(Table 3). The survival rates of embryos were severely reduced in groups B and C when the
concentration of VPA was 20 mM or higher. Additionally, the embryos died completely in group
A if the VPA concentration reached 10 mM. When the concentration was 40 mM or higher, 75%
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- 100% of embryos in all groups died. It is worth noting that group A is more sensitive to the
toxicity of VPA since this group showed 75%-100% mortality rate occurring in all experiments at
the concentrations of 5 mM or higher. The LC50 of group A is much lower than that of groups B
and C, suggesting that the VPA toxicity is developmental-stage specific (Figure 3).
3.2 Effects of vaproic acid on hatching efficiency of Japanese rice fish at different
developmental stages.
In our facility, the control embryos initiated hatching at 7+ dpf. The hatching efficiency
of the embryos was altered by VPA and found to be dose-dependent. The embryos of groups A,
B and C were able to hatch (>75%) if they were exposed to VPA concentrations below or equal
to 2mM. However, when embryos were exposed to 5 mM valproate, none of the group A
embryos, below 50% of group B embryos and below 5% of group C embryos were able to hatch
successfully (Figure 4). It is notable that group B embryos with 5 mM VPA treatment had a much
higher incidence in hatching efficiency comparing with group A or C exposed to the same
concentration of VPA. The reason for this will be discussed in the next chapter.
embryos treated with 10 mM VPA in all groups was able to hatch.

None of the

Compared with controls, 5

mM or higher concentration of VPA was able to reduce the hatching efficiency significantly in all
groups.
3.3 Morphometric analysis of Japanese rice fish exposed to valproic acid at different
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developmental stages.
3.3.1 VPA effects on the cardiovascular system
The cardiovascular development (heartbeat, circulation status and thrombus formation) of
the embryos was examined on day 6 post fertilization (for group A 4 days after, for group B 3
days after, and for group C immediately after valproate removal from the medium).
3.3.1.1 VPA effects on heart beat
Heart rates were determined for three consecutive days (6-8 dpf) in all three groups.
Usually, the control embryos start hatching after 7 dpf. To avoid hatching effects, we have
restricted our heart rate observations in ovo from 6 to 8 dpf. Here again a dose-dependent
reduction in heart rate in all groups was observed. Moreover, embryos exposed to 10 mM or
higher concentration of VPA in group A, and embryos exposed to 80 mM VPA in groups B and C,
displayed no heart beat in the 6-8 dpf period (Figure 5.1-5.3). In group A, the heart rate was
significantly reduced in embryos exposed to 5 mM. Heart rate was not reduced in group A
embryos exposed to 2 mM valproate (Figure 5.1). In groups B and C, the embryos exposed to 40
mM or lower have heart beat, however, dose-dependent reductions of the rates of heart beat in
both groups were noticed (Figure 5.2-5.3). In group A, a total of 24 embryos were exposed to 5
mM VPA, and examined on three consecutive days (6-8 dpf); only 2, 1, and 1 of 24 embryos had
heart beats on 6, 7, and 8 dpf respectively. Additionally, the mean rates of the heart beat on these
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three consecutive days were 6.58, 5.21, and 5.40 beats per minute. These heart rates are much
lower than those of groups B and C, which are above 90 beats per minute (Figure 5.1-5.3). It was
shown that VPA has a more deleterious effect on the early developmental stage (group A) of
Japanese rice fish embryos. In group B, no embryo exposed to 40 mM VPA had heart beats on 6
dpf, while 8.33% and 16.67% of group B embryos had heart beats on 7 dpf and 8 dpf
respectively (Figure 5.2). The heartbeat normally starts at 44 hrs post fertilization (Iwamatsu
stage 24), and the embryos in group B (1-3 dpf) started VPA treatment before the onset of the
heartbeats. When the embryos of group B were treated with 40 mM VPA, the heart beat of some
embryos, which should initiate around 2 dpf, were delayed due to VPA toxicity and gradually
started after 6 dpf. These data demonstrate that VPA can delay the onset of heart beat. All the
embryos of group C started the VPA treatment after their heartbeats have already initiated. The
percentage of embryos with heartbeats in group C, if they were exposed to 40 mM VPA,
decreased from 66.67% on 6 dpf, to 54.17% on 7 dpf and finally down to 50% on 8 dpf (Figure
5.3). This demonstrates that high dose VPA can inhibit heartbeat after it has already initiated
(Figure 5.3). In group A, no embryo survived if the exposure concentration of VPA was above
5mM, and the heart rates of group B embryos were reduced more sharply by increasing the
concentration of VPA comparing with those of group C embryos (Figure 5.1-5.3). To sum up, in
groups A, B and C, the VPA-induced teratogenic effects on the onset and rates of heart beats are
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dose/developmental stage-dependent.
3.3.1.2 VPA effects on thrombus formation
On 6 day post fertilization, a significant number of thrombi were noticed in the embryos
that survived valproate exposure (group A 5 mM, group B 5 mM and 10 mM, and group C 20
mM, 40mM and 80 mM subgroups). Moreover, thrombi were seen only in those embryos that
had developed heartbeats. When valproate treatment prevented initiation of heartbeat, no thrombi
were seen. Embryos of Japanese rice fish normally start heartbeats first (44 hpf, Iwamatsu
developmental stage map) and then blood circulation (50 hpf, Iwamatsu developmental stage
map). Embryos of groups A and B were exposed to VPA before the initiation of heartbeat and
blood circulation. Additionally, some embryos in group A (0-2 dpf) and group B (1-3 dpf)
exposed to higher concentration of VPA (5 mM or higher) possessed thrombi even though they
lacked blood circulation (Figure 6.1). No matter in which group, the higher the concentration of
VPA, the more thrombi appeared. In addition, with the elevated concentrations of VPA, more
thrombi were shown in the embryos without circulation on 6 dpf. Some of these embryos have
not developed onset of circulation, while the circulatory system of others was inhibited after its
onset. An interesting phenomenon is group B (1-3 dpf) embryos treated with 20 mM valproic
acid exhibited no thrombus development on 6 dpf. It was suggested that the thrombi were seen
only in those embryos that have the ability to develop blood vessels. If valproate treatment (high
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concentration of VPA) is able to stop blood vessel formation, no thrombus would have been seen.
Embryos in group C (4-6 dpf) were exposed to VPA after they had already started heartbeat and
blood circulation. Therefore, the thrombus formation in group C was probably due to the
detrimental effects of VPA toxicity which lead to injury of the endothelial cells of blood vessels
(Figure 6.1). Embryos in the late development stage (4-6 dpf) were more resistant to the
VPA-induced teratogenesis, and therefore some embryos (4-6 dpf) treated with 20mM, 40 mM or
80 mM VPA were alive and presented thrombus on 6 dpf. This is different from embryos in the
early development stage (0-2 dpf and 1-3 dpf). The onset of heartbeat is a crucial factor in the
thrombus formation. Onset of blood circulation also plays an important role in thrombus
formation. Thrombus formation is both dose and developmental-stage dependent.
3.3.1.3 VPA effects on circulation
The onset of embryonic blood circulation was also found to be dose and developmental
stage-specific (Figure 6.2). It was observed that almost all the embryos that were able to hatch
successfully had well developed circulatory vessels and the blood circulated in the body and yolk
through these vessels. However, of those embryos that were unable to hatch, the majority of
them had either no blood vessels or difficulties in obtaining blood circulation. When observed on
6 dpf, group A embryos exposed to 2 mM, and most of group B embryos exposed to 2 and 5
mM, were able to circulate blood through vessels. Less than 5% of group A embryos exposed to
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5 mM VPA, or group B embryos exposed to 10 mM VPA had vessel circulation on 6 dpf (Figure
6.2). The majority of group C embryos that were treated with 2, 5, 10 mM concentration of VPA
had blood circulation on 6 dpf. However, as development proceeded in this group, a
dose-dependent loss (5, 10 mM VPA ) of vessel circulation was noticed. With increasing
concentrations of VPA, the incidence of thrombus was elevated and the condition of thrombus
became more severe in all groups. In general, circulation could be prevented by valproate, and
finally, this could prevent embryos from hatching. Embryos exposed to 10 mM VPA or higher in
group A, 20 mM VPA or higher in group B were unable to start blood circulation. In group C,
46.875% of embryos exposed to 20 mM VPA exhibited blood circulation. This indicates that the
late developmental stage is more resistant to VPA-induced teratogenesis. When compared to
controls, the incidence of blood circulation of 20 mM VPA-treated embryos in group C was
decreased significantly (53.125% ) on 6 dpf (Figure 6.2).
3.3.2 VPA effects on the hatchlings
The hatched embryos with 2 mM VPA embryonic exposure prenatally seldom exhibited
bent tails, but they might manifest yolk edema. However, under the embryonic treatment of 4mM
VPA, the hatched embryos are probable to present bent tails, diminished body length and yolk
edema (Figure 7).
3.3.3 VPA effects on the craniofacial cartilages
42

The craniofacial cartilages were examined within 24 hrs of hatching after staining with
Alcian blue (group E: early developmental stage without circulation (0-2 dpf treatment); group L:
late developmental stage with circulation (4-6 dpf treatment)) (Table 5). The neurocranium of
Japanese rice fish embryos starts chondrification, which is to develop into cartilage or become
cartilaginous in ovo on 5 dpf (Iwamatsu stage 33). This completes prior to or after hatching until
hatchlings reach Iwamatsu stage 40. A typical Japanese rice fish embryo immediately after
hatching possesses a chondrocranium which includes auditory and nasal capsules, a
well-developed neurocranium and splanchnocranium and a minimal amount of chondral
braincase elements (Figure 8-9). The detailed values for each of the treatment groups are listed in
table 4. Six cartilages, POC, auditory capsule, PBC in the neurocranium and PT, HYS and HYO
in the splanchnocranium were not considered for measurement due to irregular (non-linear)
shapes.
3.3.3.1 Neurocranial Cartilages:
3.3.3.1.1 Neurocranium
It was observed that, in general, compared to controls the linear length of the
neurocranium of hatchings in groups E and L treated with 2 mM valproate were significantly
reduced (Figure 10 & Table 7). This indicates that VPA exerted a detrimental influence over the
entire neurocranium.
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3.3.3.1.2 Trabeculae (TC)
Compared to controls, TC was significantly reduced 8.08% in group E (0-2 dpf)
hatchlings exposed to 2 mM valproate prenatally but not in group L hatchlings (Figure 10 &
Table 7). This indicates that early developmental stages are more sensitive to the deleterious
effects resulting from VPA toxicity.
3.3.3.1.3 Epiphyseal Bar (EB)
The linear lengths of the EB in hatchlings (group E, 0-2 dpf treatment) treated with 2 mM
VPA were significantly reduced 8.17% compared with controls. EB from group L hatchlings (4-6
dpf) with 2 mM VPA treatment grow much larger than those from group E (1-3 dpf) treated with
the same concentration of VPA. This indicates that VPA toxic effects are developmental-stage
specific and that VPA toxic effects are more pronounced in the early developmental stage (Figure
10 & Table 7).
3.3.3.1.4 Anterior Orbital Cartilage (AOC)
AOC displayed significant reduction (10.19%) in linear length relative to controls only in
group E hatchlings (0-2 dpf) treated with 2 mM VPA. The development of AOC in group L (4-6
dpf) hatchlings with 2 mM VPA exposure was not significantly affected. Compared with group E
with the same concentration of VPA treatment, AOC in group L treated with 2 mM VPA grows
much longer (15.28%) (Figure 11 & Table 7). These data indicate that toxicity caused by VPA is
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predominant in the early developmental stage.
3.3.3.1.5 Anterior Basicranial Commissure (ABC)
ABC remained unaltered in hatchlings of 2 mM VPA-treated groups E (0-2 dpf) and L
(4-6 dpf) when compared with controls. It was determined that ABC was significantly longer in
group L hatchlings with 2 mM VPA treatment than it was in group E with the same treatment
(Figure 11 & Table 7). This may be due to the fact that early developmental stage suffers more
severely from VPA toxicity.
3.3.3.1.6 Basilar Plate (BP)
The linear length of BP in group E hatchlings (0-2 dpf) treated with 2 mM Valproate was
reduced significantly (4.27%) when compared with controls. BP of group E hatchlings with 2
mM VPA treatment prenatally were significantly smaller (6.17%) compared with those
correspondingly hatchlings in group L (4-6 dpf) (Figure 11 & Table 7). These data suggest that
the teratogenic effects from VPA toxicity were more remarkable in the early developmental
stage.
3.3.3.1.7 Polar Cartilage (PC)
It was shown that 2 mM VPA only decreased PC in group L hatchlings significantly
(24.47%) when exposed embryonically (Figure 11 & Table 7). VPA manifested its detrimental
impacts on PC in the late developmental stage.
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3.3.3.2 Splanchnocranium
3.3.3.2.1 Meckel's Cartilage (MC)
MC showed no reduction in 2 mM VPA-treated hatchlings of groups E and L compared
with controls (Figure 12 & Table 7).
3.3.3.2.2 Quadrate (QU)
Compared to controls, the hatchlings with 2 mM VPA exposure exhibit significantly
shorter QU in groups E and L respectively. QU of the hatchlings with 2 mM VPA exposure
prenatally in group E demonstrated significant reduction (6.33%) in length compared with those
treated with the same concentration of VPA in group L (Figure 12 & Table 7). It is observed that
the early developmental stage is most subject to the damage derived from VPA toxicity.
3.3.3.2.3 Basihyal (BH)
Compared to controls, there were no alterations in the linear lengths of BH of the
hatchlings in groups E and L respectively (Figure 12 & Table 7).
3.3.3.2.4 Ceratohyal (CH)
It was recorded that the linear lengths of CH of the hatchlings in both groups E and L
treated with 2 mM VPA were decreased significantly (7.41% for group E and 8.24% for group L)
compared to controls (Figure 12 & Table 7).
3.3.3.2.5 Basibranchial 1-3 (BB 1-3)
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BB 1-3 revealed significant reduction in the linear lengths from the hatchlings exposed to
2 mM VPA embryonically in groups E and L, compared with controls. BB 1-3 in group E with 2
mM prenatal VPA exposure were significantly shorter (10.97%) than those in group L (Figure 13
& Table 7). It was indicated that the early developmental stage (0-2 dpf)

possesses less

resistant capability to VPA toxic effects.
3.3.3.2.6 Basibranchial 4 (BB 4)
VPA produced no modification of BB 4 in any treatment groups (Figure 13 & Table 7).
3.3.3.2.7 Ceratobranchial 1 (CBR 1)
It was shown that CBR 1 of the hatchlings treated with 2 mM VPA prenatally was
reduced in length significantly only in group L when compared with controls (Figure 13 & Table
7). This indicates that CBR1 at the late developmental stage is more sensitive to VPA toxicity.
3.3.3.2.8 Ceratobranchial 2 (CBR 2)
CBR 2 displayed significant reduction in linear length only in the hatchlings of group L
treated with 2 mM VPA, when compared with controls (Figure 13 & Table 7). This indicates that
CBR2 at the late developmental stage is most subject to the toxic effects of VPA.
3.3.3.2.9 Ceratobranchial 3 (CBR 3)
Compared to controls, the linear length of CBR 3 in the hatchlings decreased
significantly (11.40%) only in 2 mM VPA-treated group L. (Figure 14 & Table 7). This indicates
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that the late development of CBR3 is more resistant to VPA-induced teratogenesis.
3.3.3.2.10 Ceratobranchial 4 (CBR 4)
Compared to controls, the linear length of CBR 4 was decreased significantly (17.46%)
only in the hatchlings of group L embryonically treated with 2 mM VPA. The linear length of
CBR 4 in the hatchlings of group L treated with 2mM VPA displayed significant reduction when
compared with those in group E (Figure 14 & Table 7). It is suggested that VPA exerts toxic
effects on CBR 4 at the late developmental stage.
3.3.3.2.11 Ceratobranchial 5 (CBR 5)
It was found that, compared to controls, hatchlings displayed significantly reduced linear
length of CBR 5 (25.27%) only in the hatchlings of group L that were embryonically exposed to
2 mM VPA (Figure 14 & Table 7). This indicates VPA-induced teratogenic effects on CBR 5 are
more apparent at the late developmental stage.
3.4 Biochemical analysis of Japanese rice fish embryos exposed prenatally and
developmentally to VPA.
To find a molecular characteristic related to VPA-induced teratogenesis in
valproate-treated Japanese rice fish, we have analyzed mRNA expression patterns for nine genes
that are related to oxidative stress (catalase, glutathione-s-transferase, glutathione reductase),
neurogenesis (iro3, nlgn3b, wnt1, shh, otx2) and cell division (shh, cyclin a2). All of these genes
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have been reported to be expressed in Japanese rice fish embryos during morphogenesis. In this
experiment, Japanese rice fish embryos were exposed to two concentrations of valproate for 48
hrs in three developmental stages (group A: 0-2 dpf; group B: 1-3 dpf; group C: 4-6 dpf). Group
A embryos were exposed to 1 and 2 mM, and groups B and C embryos were exposed to 2 and 5
mM of valproate. The treatment continued for 48 hrs with a one time change of the media at 24
hrs. The embryos in each group were sacrified for mRNA analysis immediately after treatment.
The primers used for rRT-PCR are presented in Table 5.
3.4.1 Oxidative Stress
VPA did not alter the catalase, gst, or gr mRNA expression levels indicating that VPA
toxicity probably was not the result of oxidative stress.
3.4.1.1 Catalase
The data obtained by rRT-PCR showed that the embryos treated with different
concentrations of VPA were able to maintain equal levels of catalase mRNAs within groups A, B
and C just after VPA treatment for 48 hrs (Figure 15.1). Therefore, VPA did not affect catalase
mRNA levels.
3.4.1.2 Glutathione-S-Transferase (gst)
Embryos in groups A, B and C did not show significant reduction or increase in gst
mRNA expression levels when compared to their corresponding controls. In conclusion, VPA did
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not have an impact on gst mRNA expression pattern. Glutathione-S-transferase mRNA
expression level significantly increased in controls on 6 dpf in contrast to those on 2 dpf. This
suggested that gst mRNA is expressed constitutively and upregulated as the development of
embryos go on (Figure 15.2).
3.4.1.3. Glutathione Reductase (gr)
The gr mRNA contents remained unaltered after valproate exposure in groups A, B and C
(Figure 15.3).
3.4.2 Neurogenesis
3.4.2.1 Neuroligin 3b (nlgn 3b)
The neuroligin 3b mRNA expression pattern was altered in a dose and developmental
stage-specific manner. When compared to controls, embryos of group B with 5 mM VPA
exposure showed statistically significant reductions (84.04%) in nlgn 3b mRNA levels. It is
indicated that the nlgn mRNA expression levels tend to be reduced in VPA-treated embryos, and
the extent of reduction elevates with increasing concentration of VPA. It is believed that a larger
number (n) of experiments would make this result significant. The nlgn 3b mRNA in controls
manifested an elevated expression pattern in groups B and C when compared with those in group
A, suggesting that neuroligin 3b mRNA is expressed constitutively and upregulated as the
development of embryos continues (Figure 16.1).
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3.4.2.2 Orthodenticle Homeobox 2 (Otx2)
The otx2 mRNA expression pattern was modified in a dose and developmental
stage-specific method. Compared with controls, the expression levels of otx2 mRNA were only
reduced by valproic acid in group B embryos treated with 5 mM VPA. Compared with controls
in group A, otx2 mRNA expression levels were upregulated in controls of groups B and C (on 3
dpf and 6 dpf ) (Figure 16.2). This suggested that otx2 mRNA was expressed constitutively and
its level was upregulated as the development of the embryos progressed.
3.4.2.3 Wingless-type Mouse Mammary Tumor Virus Integration Site Family, Member 1
(Wnt1)
The wnt1 mRNA expression pattern was altered in a dose and developmental
stage-specific manner. Wnt1 mRNA expression level was only reduced in embryos of group B
treated with 5 mM valproic acid. Wnt1 mRNA content of controls on 6 dpf was less than the
content on 3 dpf (P<0.0001) (Figure 16.3). It is indicated that wnt1 is constitutively expressed
and its expression level was changed by the treatment of valproic acid during 1-3 dpf for 48 hrs.
3.4.2.4 Iroquois 3 (iro3)
The data obtained by rRT-PCR showed that the embryos from groups A, B and C with
VPA treatment maintained similar amounts of iro3 mRNA content when compared with controls
(Figure 16.4). Thus, iro3 mRNA expression levels remained unaltered after valproate exposure.
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It is indicated that the toxic effects of valproic acid were not derived from modification of iro3
mRNA expression pattern.
3.4.3 Cell Division
3.4.3.1 Sonic Hedgehog (shh)
The shh mRNA expression was modified in a dose and developmental stage-specific
manner. Only in group A were shh mRNA expression levels reduced 46.35% in embryos exposed
to 2 mM VPA (Figure 17.1). This suggests that the shh mRNA expression pattern was altered by
valproic acid in the early developmental stage of embryos, which is the cell division phase
(group A: 0-2 dpf). Therefore, VPA probably manifested its teratogenesis by inhibiting cell
division during early development of embryos.
3.4.3.2 Cyclin A2 (ccna2)
The mRNA expression of ccna2 was inhibited by valproic acid treatment significantly at
2 mM concentration in group A (46.33%) and 5 mM in group C (19.37%), when compared with
the corresponding controls. Since cyclin A2 is the gene that controls the progression of cell cycle
and 0-2 dpf is the critical phase for cell division, the result suggests that VPA may exert its
toxicity by reducing cell division (Figure 17.2).
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Table 4: Treatment groups classification of Japanese rice fish embryos used for
determination of the LC50s of VPA, the effects of VPA on the cardiovascular development
and the mRNA expression levels of the related genes

Groups

VPA treatment (hour

Developmental stages at the beginning

Observations after

post fertilization)

of VPA treatment ( Iwamatsu, 2004)

VPA removal (h)

A

0-48

4-10

~96

B

24-72

17-20

~72

C

96-144

31-32

~1
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Table 5: Treatment groups classifications of Japanese rice fish embryos used for
measurement of craniofacial cartilages
Groups

VPA treatment (hour

Developmental stages at the beginning of

Observations after

post fertilization)

VPA treatment ( Iwamatsu, 2004)

VPA removal (h)

E

0-48

4-10

~96

L

96-144

31-32

~1
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Figure 3: Valproate-mediated mortality in Japanese rice fish embryos. Fertilized eggs of
Japanese rice fish within 4 hpf (A), 24 hpf (B) and 96 hpf (C) were exposed to valproate (0-80
mM) for 48 h and then transferred to clean hatching solution. The effect on mortality was
recorded on 14 dpf. The experiment was repeated 3 times and each treatment group consisted of
8 embryos. The calculated LC50 values are 1.68 ± 1.55 mM for group A (r2=0.83), 26.45 ± 1.64
mM for group B (r2=0.88) and 20.37 ± 3.30 mM for group C (r2=0.55). LC50s were calculated
from transformed data (log valproate concentration) using a nonlinear regression (curve-fit)
program (GraphPad Prism). Each data point represents the mean mortality precentage ± SEM
(n=3). These data indicate that group A embryos were more sensitive to valproate than groups B
and C.
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Table 6: The LC50 values of Japanese rice fish embryos exposed to VPA at three different
developmental stages

Group

LC50

group A

1.68 ± 1.55 mM

group B

26.45 ± 1.64 mM

group C

20.37 ± 3.3 mM
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Hatching efficiency

100

*
*

10 mM-C

2 mM-C

5 mM-B

2 mM-B

2 mM-A

Control

10 mM-B

*

*

0

*
5 mM- C

50

5 mM-A

Embryos Hatch
(%)

150

Figure 4: Hatching efficiency of Japanese rice fish embryos developmentally exposed to
valproate. Embryos at specific developmental stages (A, B, and C) were exposed to different
concentrations of valproate (0-80 mM) for 48h. Then they were transferred to clean hatching
solution. Parallel groups with no valproate served as controls. For group details see Table 4.
Hatching was recorded from 7+ dpf. Each group consists of eight embryos and the experiment
was repeated 3 times. Each bar is the mean ± SEM of 3 independent experiments. Bar head
with asterisks (*) indicate that the data were significantly different (P<0.05) from the controls
(no valproate).
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Figure 5: Heart rates of Japanese rich fish embryos exposed to Valproate during
development. Fertilized embryos were exposed to valproate (0-80 mM) for 48 h in groups A, B
and C and then transferred to clean hatching solution. Parallel groups with no valproate served as
controls. For group details see Table 4. Heart rates were examined on 6, 7, and 8 dpf. Each group
contained 8 embryos per treatment. Each bar is the mean ± SEM of three independent treatment
repetitions. Bar head with pound symbol (#) indicates that the data are significantly different
(P<0.05) from the corresponding controls (no valproate). Figure 5.1: heart rates of group A;
figure 5.2: heart rates of group B; figure 5.3: heart rates of group C. The effects of valproate on
heart rates were dose- and developmental stage-specific.
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Figure 6: The occurrence of thrombi and blood circulation observed on 6 dpf in embryos
after exposure to valproate at three different developmental stages (groups A, B, and C).
Fertilized embryos were exposed to valproate (0-80 mM) for 48 h in groups A, B and C and
then transferred to clean hatching solution. Parallel groups with no valproate served as controls.
For group details see Table 4. The incidences of thrombi and vessel circulation onset were
examined on 6 dpf. Each group contained 8 embryos per treatment. Each bar is the mean ±
SEM of three independent treatment repetitions. Bar head with asterisks (*) indicate that the
data are significantly different (P<0.05) from the corresponding controls (no valproate). Figure
6.1= Incidence of thrombi in each group observed on 6 dpf. Figure 6.2= Incidence of vessel
circulation onset in each group observed on 6 dpf. The effects of valproate on occurrence of
thrombi and vessel circulation were dose- and developmental stage-specific.
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A
(A) Control

B

C

(B) 2mM –Group C

(C) 4mM –Group C (Spine cord is curved.)

Figure 7: Representative photomicrographs displaying teratogenic effects of valproate in
hatched Japanese rice fish. Embryos (4 dpf) were exposed to 2 mM and 4 mM VPA for 48 h
(4-6 dpf) and then maintained in clean hatching solution without VPA until hatching. The
photographs were taken with an Olympus BX 40F-3 microscope at fixed magnification (40X).
Figure 7.1: control; 7.2: embryos exposed to 2 mM VPA; 7.3: embryos exposed to 4 mM
valproate. Arrow ( ) represents the area where the yolk edema was seen. In valproate-treated
hatchlings, yolk edema (7.2) and bent tail (7.3) are seen.
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Table 7: Effect of valproate on the length of neurocranial and splanchnocranial cartilages
(um) of Japanese rice fish hatchlings

Locations

Neurocranium

Splanchnocranium

Cartilag

Group E

Group E

Group L

Group L

e Name

Control

2 mM VPA

Control

2mM VPA

NRC

920±9.9

883±10.1*

945±10.0

910±9.8*

TC

198±4.6

182±2.5*

200±3.9

186±8.7

EB

306±4.7

281±4.5*

319±4.3

311±4.9

AOC

216±5.1

194±7.2*

229±4.3

229±8.2

ABC

435±6.6

424±5.6

453±7.1

444±5.3

BP

445±6.1

426±7.3*

457±11.3

454±5.6

PC

56±2.4

49±2.7

61.7±2.9

46.6±3.8*

MC

118±4.3

116±2.0

125±3.0

118±4.0

QU

335±4.8

311±7.2*

346±4.3

332±6.0*

BH

158±8.6

167±8.7

171±5.8

161±7.5

CH

270±5.8

250±5.9*

279±4.1

256±4.7*

BB 1-3

339±7.3

284±7.6*

360±5.7

319±8.7*

BB 4

43±1.8

41±2.3

46±2.6

47±3.0
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CBR 1

211±6.2

199±3.9

227±6.0

189±6.1*

CBR 2

212±5.8

200±3.8

227±5.0

199±4.0*

CBR 3

213±6.5

208±3.7

228±4.7

202±4.4*

CBR 4

243±5.9

230±4.4

252±6.6

208±7.0*

CBR 5

169±5.9

163±5.3

186±7.4

139±13.8*

Japanese rice fish embryos were exposed to 2 mM VPA with or without circulation for 48
hrs at two different developmental stages (group L: treatment during 4-6 dpf; group E: treatment
during 0-2 dpf). After 48 hrs treatment, they were transferred to clean hatching solution to allow
the embryos to hatch. For group details see Table 5. Groups E and L hatchlings within~24 hrs
after hatching were preserved in 4% PFA and used for cartilage staining with alcian blue. The
cartilage length was measured with an Olympus BX 40F-3 microscope with image analysis
software. NRC= Neurocranium; EP= Ethmoid plate; TC= Trabecular cartilages; EB= Epiphyseal
bar; AOC = Anterior orbital cartilages; ABC= Anterior basicranial commisure; BP = Basilar plate;
PC = Polar cartilages; MC = Meckel’s cartilage (lower jaw); QU = quadrate; BH= Basihyal; CH
= Ceratohyal; BB1-3 = Basibranchials 1-3; BB4 = Basibranchial 4; CBR 1-5 = ceratobranchials
1-5; GWC= Groups with circulation; GWOC= Groups without circulation. The nomenclature of
the cartilages used in this communication was obtained from Langille and Hall (1987). The
results are expressed as mean ± SEM. The data are analyzed by unpaired t test. Asterisks (*)
indicate that the value is significantly different from corresponding controls (no valproate). The
deleterious impacts caused by VPA on splanchnocranial cartilages are developmental-stage
dependent.
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Figure 8: Representative photomicrographs of neurocranial cartilages of Japanese rice fish
hatchlings (14 dpf). The hatchlings (14 dpf) were stained with alcian blue and pictures (100X)
were taken with an Olympus BX 40F-3 microscope. The picture presented above displays the
locations of the different cartilages in the neurocranium (dorsal view) of Japanese rice fish
hatchlings.
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Figure 9: Representative photomicrographs of splanchnocranial cartilages of Japanese rice
fish hatchlings (14 dpf). The hatchlings (14 dpf) were stained with alcian blue and pictures
(100X) were taken with an Olympus BX 40F-3 microscope. The picture presented above
displays the locations of the different cartilages in the splanchnocranium (dorsal view) of
Japanese rice fish hatchling
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Figure 10: Effects of valproate on the development of neurocranial cartilages (neurocranium,
trabeculae and epiphyseal bar) of Japanese rice fish embryos. Embryos with (group L: 4-6 dpf
treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48 hrs, with
a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment, the
embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4%
PFA within~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#)
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment. The deleterious
impacts caused by VPA on neurocranial cartilages are developmental-stage dependent.
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Figure 11: Effects of valproate on the development of neurocranial cartilages (arterior orbital
cartilage, anterior basicranial commissure, basilar plate and polar cartilage) of Japanese rice fish
embryos. Embryos with (group L: 4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation
were exposed to 2 mM VPA for 48 hrs, with a one time change of medium at the same concentration of
VPA at 24 hr. After 48 hrs treatment, the embryos were transferred to clean hatching solution, and then
maintained with a 50% static renewal of medium per day until they hatched. For group details see Table 5.
The hatchlings were preserved in 4% PFA within ~24hrs after hatching and were stained with 0.1%
Alcian blue. The cartilage length was measured with an Olympus BX 40F-3 microscope with image
analysis software. The results are expressed as mean ± SEM. The data were analyzed by unpaired t test.
Asterisks (*) indicate that the values are significantly different (P<0.05) from the corresponding controls
and pound symbol (#) indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment.
The deleterious impacts caused by VPA on neurocranial cartilages are developmental-stage dependent
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Figure 12: Effects of valproate on the development of splanchnocranial cartilages (Meckel’s
cartilage, quadrate, basihyal and ceratohyal) of Japanese rice fish embryos. Embryos with (group L:
4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48
hrs, with a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment,
the embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4%
PFA within ~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#)
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment. The deleterious
impacts caused by VPA on splanchnocranial cartilages are developmental-stage dependent.
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Figure 13: Effects of valproate on the development of splanchnocranial cartilages (basibranchials
1-3, basibranchial 4, ceratobranchials 1-2) of Japanese rice fish embryos. Embryos with (group L:
4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48
hrs, with a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment,
the embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4%
PFA within~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#)
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment.. The deleterious
impacts caused by VPA on splanchnocranial cartilages are developmental-stage dependent.
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Figure 14: Effects of valproate on the development of splanchnocranial cartilages (ceratobranchials
3-5) of Japanese rice fish embryos. Embryos with (group L: 4-6 dpf treatment) or without (group E: 0-2
dpf treatment) circulation were exposed to 2 mM VPA for 48 hrs, with a one time change of medium at
the same concentration of VPA at 24 hr. After 48 hrs treatment, the embryos were transferred to clean
hatching solution, and then maintained with a 50% static renewal of medium per day until they hatched.
For group details see Table 5. The hatchlings were preserved in 4% PFA within~24hrs after hatching and
were stained with 0.1% Alcian blue. The cartilage length was measured with an Olympus BX 40F-3
microscope with image analysis software. The results are expressed as mean ± SEM. The data were
analyzed by unpaired t test. Asterisks (*) indicate that the values are significantly different (P<0.05) from
the corresponding controls and pound symbol (#) indicates the difference (P<0.05) of the data with group
E at 2 mM VPA treatment. The deleterious impacts caused by VPA on splanchnocranial cartilages are
developmental-stage dependent.
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Table 8: List of primers used in semi-quantitative RT-PCR (rRT-PCR) amplification of the
mRNAs of Japanese rice fish embryo.
mRNA

Sense (5-3)

Antisense
(5-3)

Product
(bp)

GenBank
accession/
Ensembl number

β-actin

cctgaccctgaagtat
ccca

agcgacaagatgag
ctggtt

542

ENSORLT00000
017152

catalase

gcggtacaacagcgc
agatgaag

ggatggacggccttc
aagttc

171

ENSORLT00000
002176

Glutathione reductase
(gr)

ggactactcctgcattc
ccacag

cattgactcttcctgc
gtgtgatg

165

ENSORLT00000
000771

Glutathione-S-transfera
se (gst)

gaacctgcagggcta
caacc

ggccctcaaacatgc
gttgg

241

GenBankX95200

Neuroligin 3b (nlgn3b)

gatgaggtgccttatgt
gtttg

ccactttggtggcac
ggtagtg

292

NM_001201508

Iroquois homeobox
protein iro3 (iro3)

ccagacccaaaaatg
ccacc

ccttgtaaatcctcat
agccg

221

AB098317

Wingless-related
MMTV integration site
1 (wnt1)

gtgggagatttcctca
aggac

cagcaccagtggaa
agtgcag

338

AJ243208

Sonic hedgehog (shh)

gatgaggagaacacc
ggagcc

cttccaccgccagtct
ggac

241

AB007129

Orthodenticle
homeobox2 (otx2)

ggcctgagcttaacta
cctc

ggactcgggaagatt
gattgattttc

201

AJ000939

CyclinA2 (ccna2)

gctacatgaagaagc
agcctg

gactttgagcaccag
atgctc

311

ENSORLT00000
024919
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Figure 15: Effects of valproate on catalase, gst and gr mRNA expression in Japanese rice
fish at three different developmental stages. Total RNA was prepared from 6-8 pooled
embryos after valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C). This
was reverse transcribed and analyzed by rRT-PCR using β-actin primers as internal control. For
group details see Table 4. The results were expressed as the ratio of relative band intensity of the
target gene to the band intensity of the β-actin gene. We took the log of the ratios, and these
values were used for one way ANOVA followed by Tukey’s post-hoc multiple comparison test;
p<0.05 was considered as significant. Each data point is the mean ± SEM of 4 separate
experiments. Bar heads with an asterisk (*) indicate that the value is significantly different from
the corresponding control (no valproate). Figure 15.1: catalase; Figure 15.2: gst; Figure 15.3: gr.
The data indicate that VPA teratogenesis may not be derived from oxidative stress.
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Figure 16: Effects of valproate on nlgn3b, otx2, wnt1 and iro3 mRNA expression in
Japanese rice fish at three different developmental stages. Total RNA was prepared from 6-8
pooled embryos after valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C).
This was reverse transcribed and analyzed by rRT-PCR using β-actin primers as internal control.
For group details see Table 4. The results were expressed as the ratio of relative band intensity of
the target gene to the band intensity of the β-actin gene. We took the log of the ratios, and these
values were used for one way ANOVA followed by Tukey’s post-hoc multiple comparison test;
p<0.05 was considered as significant. Each data point is the mean ± SEM of 4 separate
experiments. Bar heads with an asterisk (*) indicate that the value is significantly different from
the corresponding control (no valproate). Figure 16.1: nlgn3b; Figure 16.2: otx2; Figure 16.3:
wnt1; Figure 16.4: iro3.
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Figure 17: Effects of valproate on shh and ccna2 mRNA expression in Japanese rice fish at
three different developmental stages. Total RNA was prepared from 6-8 pooled embryos after
valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C). This was reverse
transcribed and analyzed by rRT-PCR using β-actin primers as internal control. For group details
see Table 4. The results were expressed as the ratio of relative band intensity of the target gene to
the band intensity of the β-actin gene. We took the log of the ratios, and used these values for one
way ANOVA followed by Tukey’s post-hoc multiple comparison test; p<0.05 was considered as
significant. Each data point is the mean ± SEM of 4 separate experiments. Bar heads with an
asterisk (*) indicate that the value is significantly different from the corresponding control (no
valproate). Figure 17.1: shh; Figure 17.2: ccna2.
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CHAPTER 4
DISCUSSION
Valproate is preferred to treat absence seizures, generalized tonic-clonic seizures,
myoclonic seizures and partial seizures. In addition, it is also very effective for treating bipolar
disorder and migraine. Epilepsy is a common neurological disorder that affects 0.5-1 % of
pregnant women (Fairgrieve, 2000; Holmes et al., 2001). Approximately 0.3% of all pregnant
women are in need of a balanced antiepileptic drug treatment (Morrell, 2002), even though
these drugs (carbamazepine, valproic acid, phenobarbital, phenytoin, lamotrigine, etc.) are
known to be teratogens to children born to mothers taking them during pregnancy. These
epileptic drugs are responsible for a wide spectrum of fetal malformations and severe cognitive
disorders in the offspring, such as fetal valproate syndrome (FVS) and/or autistic spectrum
disorders (ASDs). Since valproic acid is very specialized to treat some types of convulsive
disorders and has relatively less sedative effects, it is widely used worldwide. A significant
portion of pregnant women with epilepsy take valproate, either as monotherapy or as a part of
polytherapy (Kini, 2006). The embryonic and fetal damages caused by antiepileptic drugs are
described into three major categories (Ornoy, 2009): (1) Elevated risks of major congenital
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anomalies include neural tube defects, cardiovascular, orofacial and digital abnormalities,
deformities of eye, skin, abdominal wall, brain, respiratory tract and genitourinary systems, etc.;
(2) A specific syndrome, ‘Fetal Valproate Syndrome’, presented with facial dysmorphic features
(figure 2), but also involves damages to other organs, such as the neural tube;
(3)Neurodevelopmental disorders that affect cognitive, social and verbal skills, and lead to
stereotypic behaviors, such as autism-like symptoms.
It is evident from the present experimental results that Japanese rice fish embryos
exposed to valproate during development displayed several measurable phenotypic end points
analogous with human FVS. These end points were especially apparent in the cardiovasculature,
neurocranial and splanchnocranial cartilages. Human FVS which is characterized by distinctive
facial appearance, a cluster of major and minor anomalies (Table 2), and dysfunctions of CNS
(Kozma, 2001). Our studies were focused on some of the phenotypic features that were altered
by VPA in the Japanese rice fish, such as cardiovascular and craniofacial abnormalities that
appear to correlate with the phenotypes observed in human FVS. Our data demonstrate that
valproate is a teratogen in Japanese rice fish, and the teratogenic effects are specific to the
developmental stages of the embryos. Usually, the earlier the exposure, the more severe the
deleterious effects. It is well known that during morphogenesis, each tissue and organ have
critical phases during which their development may be disrupted by various teratogens.
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Therefore, to find stage-specific effects, in our model, embryos were exposed to valproate at
three stages of development (groups A, B and C) (Table 4). Group A embryos were treated with
VPA during 0-2 dpf, group B embryos during 1-3 dpf, and group C embryos during 4-6 dpf. 0-2
dpf and 1-3 dpf are critical periods for cell division and neurogenesis respectively. 4-6 dpf is the
period of time after formation of the cardiovascular system. The calculated LC50 as determined
on 14 dpf suggests that the embryos, at early stages of development (group A), were more
sensitive to valproate than those in late stages (groups B and C). A recent study in zebrafish
embryos by Selderslaghs et al. (2009) determined IC50 after exposing 2-4 hpf embryos to VPA
continuously for 24, 48, 72, and 144h. In an earlier study in zebrafish, Gurvich et al. (2005)
reported that valproate concentrations higher than 3 mM were cytotoxic, leading to rapid
developmental arrest and cell lysis (the valproate exposure period was 5.3- 24 hpf). Although the
experimental conditions and the developmental stages in which the zebrafish embryos were
exposed to valproate were different from our studies with Japanese rice fish (Gurvich et al., 2005;
Selderslaghs et al., 2009), it is evident that Japanese rice fish embryos were relatively more
resistant to valproate in late stages of development (groups B and C; LC50s are 26.45±1.64 mM
and 20.37±3.30 mM, respectively, n= 3), compared with zebrafish (LC50 for 48 h exposure is
2.09 mM; Selderslaghs et al., 2009). In addition, we consider that the culture medium also affects
the sensitivity of the Japanese rice fish embryos to valproate. We added NaHCO3 (∼2.38 mM) to
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the hatching solution as it is required for maintaining the pH of the embryo-rearing medium.
Bicarbonates have been demonstrated to compete with valproate during cellular uptake in
Dictyostelium, zebrafish and xenopus (Terbach et al., 2011). Therefore, because of the
competition, we expect that the actual concentration of valproate available to the embryo in
Japanese rice fish to induce toxicity is significantly lower than that of the calculated LC50 values
determined during the present experiments.
The deleterious effects of valproate on cardiovascular development, in our studies, were
restricted to increased thrombus formation, delayed blood circulation, and lower heart rates
which were found to be affected significantly and are dose and developmental-stage specific.
These effects were observed in each VPA treatment group. Embryos treated with higher
concentrations of VPA displayed more severe effects. In addition, embryos treated with VPA at
early developmental stages were more sensitive to VPA toxicity. Thrombi were seen only in
those embryos which were able to develop heart beat. If embryos exposed to VPA before they
developed blood circulation (groups A and B), some embryos showed thrombus formation on 6
dpf with heart beating but without onset of blood circulation. This may be due to the reason that
blood vessels cannot develop normally to allow blood flow under VPA treatment, and thus
thrombi appear. However, some embryos exposed to high concentration of VPA (20 mM)
developed heart beat but did not exhibit thrombus formation. This suggests that the detrimental
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impacts of high dose VPA are more severe than those of low dose VPA, and high dose VPA
apparently prevents the formation of blood cells. Therefore, no thrombus appeared. When blood
vessels developed before VPA treatment (C group), the VPA displayed its toxicity by acting
directly on the blood vessels to cause thrombus formation. Additionally, the initiation of blood
circulation was delayed in valproate exposed embryos in a dose and developmental-stage
dependent manner. Moreover, group C embryos, which had established blood circulation prior to
exposure to valproic acid, did not undergo any significant alterations in blood circulation during
the 48 hrs of valproate exposure. If these embryos (group C) were then maintained in clean
hatching solution and allowed to continue developing, thrombi became apparent, vessel
circulation got slower or stopped, and the embryos were either unable to hatch or died (data not
shown). The heart rate was determined on 6th, 7th and 8th dpf when there was no valproate in the
medium.

Our data indicate that the heart rate of the embryos was reduced in a dose and

developmental-stage specific manner. It was also manifested that VPA can inhibit heart beating
even if it had already initiated. Several studies have indicated that valproate affects blood vessel
development by inhibiting angiogenesis (Michaelis et al., 2004). In Jcl :ICR mouse,
administration of valproic acid to the mother induced fetal cardiovascular abnormalities such as
ventricular septal defect, endocardial cushion defect, transposition of the great arteries, double
outlet right ventricle, tricuspid atresia and hypoplastic left heart syndrome(Sonoda et al., 1993).
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In murine pluripotent embryonic stem cells, differentiation of cardiomyocytes was inhibited by
valproate in a dose-dependent manner (Na et al., 2003). Moreover, valproate inhibited the
differentiation of embryonic heart cells by reducing the contractile activity in chick heart
micromass and D3 mouse embryonic stem cell-derived cardiomyocytes in vitro (Ahir and Pratten,
2011). Although the parameters we were able to measure in cardiovascular disruption were
limited (formation of thrombi, delay in vessel circulation and reduced heart rate), we expect that
these defects in Japanese rice fish are the result of inhibition of angiogenesis (Michaelis et al.,
2004).
Healthy cardiovascular development plays an important role in the successful hatch.
Therefore, Japanese rice fish embryos that were able to hatch needed to have well-developed
circulatory vessels and normally developed blood circulation. Hatching efficiency is also dose
and developmental-stage specific. Embryos treated with higher concentrations of VPA had less
possibility to hatch. Embryos treated with VPA at early developmental stages were asssociated
with decreased incidence of hatching. The Japanese rice fish hatchlings developed yolk edema,
bent tails, and reduced body length after valproate exposure. These changes are believed to be
analogous to the spinal anomalies observed in human children with FVS.
Our analyses of craniofacial cartilages indicate that valproate induced a phenomenon of
microcephaly in Japanese rice fish (Table 7). We noticed that although B and C group embryos
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have higher LC50 values of valproate compared to group A, the successful hatching of these
embryos (B and C) was not seen in those treated with concentration of VPA greater than 10 mM.
This indicates that the morphogenesis of the embryos treated with concentrations of VPA greater
than 10 mM was significantly affected by sublethal concentrations of valproate. Therefore we
have analyzed the cartilages of the neurocranium and splanchnocranium of those embryos that
hatched successfully (Table 7). The embryos of two treatment groups (Table 5), group E: 0-2 dpf
VPA (without circulation) or group L: 4-6 dpf VPA (with circulation), were preserved in 4% PFA
within 24 h of hatching and stained with Alcian Blue (Hu et al., 2009). Previously, the
preservation of hatchlings was done at 10 dpf, and if an embryo hatched earlier (in our culture
conditions the embryos initiate hatching after 7 dpf), they were maintained in hatching solution
without food until 10 dpf (Hu et al., 2009). In the present experiment, to avoid post hatch growth,
we preserved the embryos within 24 hrs of hatching.

We observed that the measured length of

the neurocranium and other cartilages in control hatchlings (untreated embryos) were
significantly shorter than those we reported in our previous studies (Hu et al., 2009), since our
previous studies measured cartilages in Japanese rice fish on 10 dpf. Our current data indicate
that valproate significantly reduced the linear length of the neurocranium in both groups E and L
embryos when compared with controls. Epidemiological studies also showed that children
exposed to valproate prenatally have microcephaly (Almgren et al., 2009). However,
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macrocephaly not microcephaly is considered as the most consistent phenotypic feature of
autism spectrum disorder (ASD). To find VPA-sensitive neurocranial and/or splanchnocranial
features, we have extended our investigation to 6 individual cartilages in the neurocraniuam (TC,
ABC, EB, PC, AOC, BP) and 11 individual cartilages in the splanchnocranium (MC, QU, BH,
CH, BB 1-3, BB4 and 5 CBRs). We found that compared to controls the linear lengths of TC, EB,
AOC and BP in the neurocranium and QU, CH, and BB1-3 in the Splanchnocranium were
significantly reduced in group E hatchlings exposed to 2 mM valproic acid during embryonic
development (Table 7). It was also shown that, compared to controls, the linear lengths of PC in
the neurocranium and QU, CH, BB 1-3, and CBR 1-5 in the splanchnocranium were reduced in
group L hatchlings exposed to 2 mM valproic acid during embryonic development. Therefore, it
appears that the reduction in the linear length of the neurocranium is the result of cumulative
reductions of the component cartilages.
The third aim of this study was to find an affected molecular marker of FVS and/or ASD.
For that, we have analyzed mRNA expression levels of nine genes (catalase, gst, gr, nlgn3b, otx2,
wnt1, iro3, shh and ccna2) in Japanese rice fish embryos at three developmental stages (Table 4)
exposed for 48 hrs to two different concentrations of valproic acid (for group A, 1 and 2 mM, for
groups B and C, 2 and 5 mM) (Wu et al., 2012). The selected genes belong to three categories;
oxidative stress (catalase, gr and gst), neurogenesis (nlgn3b, Iro3, wnt1 and otx2) and regulation
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of cell division (cyclin a2 and shh). The expression of many of the selected genes has been
shown to be altered by valproate in human and rat (Graf et al., 1998; Bambini-Junior et al., 2011:
Tung and Winn, 2011). Analysis of mRNA was done by rRT-PCR (Hu et al., 2008) using β-actin
as internal control (Wang et al., 2006; Wu et al., 2008; 2011). The oxidative stress-related genes
(gst, gr, and catalase) have been shown to be constitutively expressed in Japanese rice fish
during development (Wu et al., 2011). Although oxidative stress is a potential cause of
teratogenesis, surprisingly, compared to controls, we did not find any significant alteration in the
mRNA expression pattern of catalase, gr and gst mRNA in Japanese rice fish embryos due to
exposure to valproate at any stage of development (Figure 15). Epileptic children exposed to
VPA also displayed no significant alterations in serum levels of catalase (Peker et al., 2009).
Therefore, it appears that valproate-induced teratogenesis in Japanese rice fish is mediated
through genes other than those that participate in mediating the process of oxidative stress.
As valproate is able to induce neural tube defects in human embryos, we have analyzed
the mRNA expression patterns of five genes (nlgn3b, iro3, wnt1, otx2, shh) that are expressed in
the brain of Japanese rice fish embryos. Neuroligins (nlgn) are a family of postsynaptic
cell-adhesion molecules that play roles in synaptic maturation through association of their
presynaptic partners the neuroxins (nrxn) (Ichtchenko et al., 1995; 1996). Our data indicate that
expression of nlgn3b mRNA is developmentally regulated in Japanese rice fish and tended to be
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reduced in all valproate-treated groups compared to the corresponding controls. Valproate
modulates the gene expression patterns of nlgn and nrxn in mice (Kolozsi et al., 2009). Iro3
belongs to Iroquois family of homeoproteins and is constitutively expressed in vertebrates, flies,
and nematodes (Gomez-Skarmeta and Modolell, 2002). In zebrafish, Iro3 has been indicated to
inhibit formation of motoneurons and to facilitate formation of interneurons (Lewis et al., 2005).
However, our analysis by rRT-PCR indicated that the expression of iro3 mRNA in Japanese rice
fish is constitutive and remained unaltered either during development or after valproate exposure
(Figure 16.4). This suggests that iro3 is not a potential target of valproate in Japanese rice fish
embryogenesis.
Our analysis of mRNA expression of shh, wnt1 and otx2 showed that the mRNA
expression levels of wnt1 and otx2 genes were significantly reduced only in B group (1-3 dpf
exposure) embryos treated with 5 mM VPA. In the other two treatment groups (A and C), these
mRNAs remained unaltered. Shh was significantly reduced in group A (2 mM), and in the other
groups (groups B and C) it remained unaltered. The developmental stage specific response of
these genes cannot be explained properly from this study. However, available literature indicates
that the teratogenic effects of valproate are also mediated by wnt1 signaling molecules
(Shimshoni et al., 2007). Shh played a central role in cell proliferation, differentiation and
patterning by activating the hedgehog signaling pathway. Polydactyly/arhinencephaly (Pdn/Pdn)
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mice exposed to valproate during gestation have exencephaly, but shh mRNA content remained
unaltered (Maekawa et al., 2005). Otx2 is recognized as an early head-domain marker (Bliz and
Cho, 1995; Pannese et al., 1995). Microarray analysis in mouse embryos exposed to valproate
prenatally identified several genes including otx2 as potential target genes of valproate-induced
teratogenesis (Kultima et al., 2010). In Japanese rice fish, further studies are needed to
understand the mechanisms of wnt1, shh and otx2 regulation by valproate.
Our data further indicate that ccna2 mRNA expression during embryogenesis of Japanese
rice fish was reduced by valproic acid in a developmental stage and dose specific manner. The
cyclins and their cyclin-dependent kinase partners (CDKs), are the basic components of the
machinery that regulates the passage of cells through cell cycle. Cyclin A2 deficiency is marked
by early embryonic lethality. Valproate is able to downregulate cyclin A expression in gastric
carcinoma cell lines (Zhao et al. 2011). Therefore, abnormality in cell division due to disruption
in ccna2 expression probably is the partial reason to explain the developmental delay and
reduced hatching efficiency by valproate as we observed in our model.
Although the molecular endpoints are not established from this study, the present
investigation indicates that some of the consequences of damages induced by valproate such as
organ-specific effects in heart and blood vessels, dysmorphogenesis in neurocranial cartilages,
and modification in neuronal gene expression, in Japanese rice fish are parallel with other
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organisms such as zebrafish and have potential to provide an opportunity to use the Japanese rice
fish as a model to study FVS and ASD.
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CHAPTER 5
CONCLUSIONS AND FUTURE WORKS
In this study, the Japanese rice fish was considered as a unique non-mammalian vertebrate
model to study VPA teratogenesis. The higher the concentration of VPA in each group, the more
incidence of death happened. The calculated LC50 value of group A (treatment during 0-2 dpf)
was 1.68 ± 1.55 mM, which was much lower than that of group B (treatment during 1-3 dpf; LC50
for group B was 26.45 ± 1.64 mM ) or group C (treatment during 4-6 dpf; LC50 for group C was
20.37 ± 3.3 mM). VPA has deleterious effects on cardiovascular development. The experiments
manifested that VPA reduced heart rates, increased incidence of thrombus and inhibited onset of
circulation in each group. VPA also decreased hatching efficiency, and resulted in axial
malformations. Yolk edema and curved spinal cord were viewed on hatchlings treated with VPA
prenatally. The higher the concentration of VPA the embryos were treated with, the more severe
the effects were. The earlier the exposure, the more dangerous the VPA treatments were. In
addition, VPA caused deformed craniofacial cartilages. The length of the neurocranium, quadrate,
ceratohyal and basibrancials 1-3 was reduced in both groups E (0-2 dpf) and L (4-6 dpf).
Trabeculae, epiphyseal bar, anterior orbital cartilage and basilar plate displayed reduction of
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length only in group E (0-2 dpf). Polar cartilage and ceratobranchials 1-5 become shorter only in
group L (4-6 dpf). However, anterior Basicranial commissure, meckel's cartilage, basihyal and
basibrancial 4 remained unaltered. While there are no conclusive outcomes of craniofacial
cartilages drawn from this study, most of the neurocranial and splanchnocranial cartilages were
modified by VPA. If the neurocranial or splanchnocranial cartilage became malformed through
VPA treatment, the length of it would be reduced. The experiments revealed that VPA induced the
abnormal morphological features (yolk edema, bent tails and microcephaly) in the hatchlings, and
the embryos at early developmental stages are more sensitive to VPA toxicity. Some genes (gst, gr
and catalase) that were indicated to be involved in oxidative stress remained unaltered in VPA
treated-embryos, however, the expression levels of some genes (nlgn3b, otx2, wnt1) correlated
with neurodevelopment were modified only in 5 mM VPA-treated embryos of group B (1-3 dpf).
Shh and cyclin A2 are associated with cell division, and their expression levels were all reduced in
embryos treated with 2 mM VPA at the early developmental stage (group A, 0-2 dpf). The early
developmental stage (0-2 dpf) is known to be a very crucial period for cell division. Hence, shh
and cyclin A2 were indicated to be implicated in the VPA-induced teratogenesis, e.g. neural tube
defects, by interrupting continuation of cell cycles. The teratogenic features of Japanese rice fish
induced by VPA were analogous to those of human FVS. In addition, all of these available
characteristics which could be regarded as parameters of FVS evaluation have potential to validate
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this Japanese rice fish as a certified and beneficial model to study VPA-induced teratogenesis,
even though more intensive investigation is needed to complete this validation.
Several problems remain unsolved from this study. These provide some additional
directions for future investigation. Most Children affected with FVS have neurodevelopmental
disorders and show autistic-like behaviors, affecting the cognitive, verbal and communicative
abilities. Autism spectrum disorder (ASD) is behaviorally defined, and therefore any
neurodevelopmental disorders displaying autistic-like behaviors will be attributed as ASD. The
Japanese rice fish can further be used to detect their behaviors induced by VPA to evaluate their
potential as a model to study ASD. Epidemiological studies report the ratio of males to females
diagnosed with autism spectrum disorder (ASD) is 4.3: 1.0 (Fombonne, 2003) and the molecular
mechanism of this phenomenon is as yet unknown. Thus, scientists can concentrate on the
epigenetic modification of genes, such as Dmy, to study the gender specific induction of ASD.
Dmy (dmrt1bY; DM-domain gene on the Y chromosome), the male determining gene, is only
found in Japanese rice fish (Oryzias latipes) (Matsuda et al., 2002, 2003) and its nearest relative
Oryzias curvinotus (Kondo et al., 2003).
In our study, we did not establish detailed and specific molecular endpoints. However
several genes were suggested to be involved in the pathogenesis of FVS induced by VPA. In the
future, it will be desirable to do real-time reverse transcription PCR to test the expression patterns
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of these genes by quantifying their mRNAs. In addition, it will be desirable to do in situ
hybridization to detect the locations of these genes and to measure their expression levels.
Although we hypothesize that oxidative stress induced by VPA results in the pathogenesis of FVS,
there were no alterations in the oxidative stress related genes (gst, gr, catalase) that we evaluated in
this study. In future, it will be desirable to determine whether other pathways related to oxidative
stress are affected. Consequently, lipid peroxidation and the ratio of NAD+: NADH which are
indicators of the redox state of a cell, are proposed as potential test parameters.
From this study we have established that most neurocranial and splanchnocranium
cartilages were affected by VPA. Neural crest (NC) cells are the precursors of these cartilages.
Many signal molecules, such as sonic hedgehog (shh), fibroblast growth factor (fgf), Wingless
(wnt) and Notch, are associated with the migration of NC cells from the CNS. Therefore, in the
future, investigations on these signaling molecules and their alterations by VPA are necessary.
Until now only one medication, risperidone, has been approved by the Food and Drug
Administration (FDA) of the USA for the pharmacologic management of autistic-like behaviors in
Children. After establishing this animal model, we can further our research to test the ability of
some natural products, such as Ginseng and Ginkgo biloba, as potential preventive agents for the
FVS and/or ASD (autism spectrum disorder). It is promising that some natural products are more
effective with less side effects.
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